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Abstract 
Attenuated measles virus (MV) vaccine strains preferentially infect, replicate in and thus 
destruct cancerous cells. In recent years, it has become evident that therapeutic success of 
oncolytic virotherapy largely depends on the modulation of the immune system. MV-mediated 
oncolysis induces an immunogenic cell death (ICD), which provides the basis to enhance or 
reinitiate a sustained antitumor immune response. In clinical testing, salvage therapy with 
oncolytic MV has led to complete tumor resolutions, demonstrating its therapeutic potential. 
However, extensive therapeutic efficacy is limited to a minority of patients. Thus, efforts are 
put into preclinical research to generate more potent MV vectors. 
Many strategies in cancer immunotherapy aim to augment T cell responses against tumor cells. 
Bispecific T cell engagers (BiTEs) simultaneously engage T cells and tumor cells. BiTE-
mediated T cell engagement activates the engaged T cell and specifically directs its cytotoxic 
potential towards the crosslinked tumor cell. BiTE therapy has achieved compelling clinical 
success in the treatment of B cell malignancies. However, BiTEs have failed to demonstrate 
efficacy against solid tumors so far. Moreover, short terminal half-life of BiTEs requires 
continuous intravenous infusion and systemic administration of BiTEs can cause severe or even 
fatal side effects. 
We hypothesize that tumor-targeted expression of BiTEs by oncolytic MV enhances therapeutic 
efficacy, as compared to either monotherapy alone. Furthermore, we hypothesize that tumor-
restricted BiTE-expression reduces systemic exposure to BiTEs and thus increases safety of 
BiTE therapy. To test these hypotheses, MVs encoding BiTEs were generated (MV-BiTE). 
MV-BiTE vectors were characterized in vitro in terms of replication kinetics, oncolytic activity 
and BiTE expression. BiTEs produced by MV-BiTE-infected cells were purified to evaluate 
binding specificity and BiTE-mediated T cell cytotoxicity in vitro. Therapeutic efficacy of MV-
BiTE in terms of survival was demonstrated using syngeneic and xenogeneic tumor models. 
For all studies, no signs of MV-BiTE-related toxicities were observed and BiTE plasma levels 
of MV-BiTE-treated mice remained below detection limit. 
Conclusively, tumor-targeted expression of BiTEs by oncolytic MV is feasible and prevented 
systemic exposure to BiTEs. Moreover, MV-BiTE treatment demonstrated therapeutic efficacy 
in different models of solid tumors in vivo. The MV-BiTE constructs constitute a modular 
vector platform that can be adapted to target any tumor antigen of choice. Thus, MV-BiTE 
therapy represents a promising approach for individualized cancer immunovirotherapy. 
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Zusammenfassung 
Abgeschwächte Viren des Masernvirus-Impfstammes infizieren und replizieren präferentiell in 
Krebszellen, was zur Zerstörung der infizierten Krebszelle führt. In den vergangenen Jahren 
wurde bewiesen, dass der Erfolg der onkolytischen Virustherapie zu einem Großteil von der 
Modulation des Immunsystems abhängt. Masernvirus-vermittelte Onkolyse induziert einen 
immunogenen Zelltod, welcher die Grundlage für die Verstärkung oder Reinitialisierung einer 
anhaltenden Anti-Tumor-Immunantwort bereitet. In klinischen Studien mit onkolytischen 
Masernviren konnten Tumore in austherapierten Krebspatienten vollständig zurückentwickelt 
werden, was das therapeutische Potential von Masernviren eindrucksvoll demonstriert. Jedoch 
werden solch umfangreiche therapeutische Effekte nur bei wenigen Patienten erzielt. Aus 
diesem Grund sind Wissenschaftler in der präklinischen Forschung darum bemüht potentere 
Masernviren zu entwickeln.  
Viele Strategien in der Krebsimmuntherapie versuchen gezielt die T-Zell-Antworten gegen 
Krebszellen zu verstärken. BiTE-Antikörper (bispecific T cell engager) sind bispezifische 
Antikörper, die T-Zellen und Krebszellen miteinander verbinden können. Die BiTE-vermittelte 
T-Zell-Bindung aktiviert die T-Zelle und richtet ihr zytotoxisches Potential spezifisch gegen 
die verbundene Krebszelle. Die BiTE-Therapie hat überzeugende klinische Erfolge in der 
Behandlung von bösartigen B-Zell-Erkrankungen erzielt. Jedoch haben BiTE-Therapien bisher 
keine Wirksamkeit gegen solide Krebserkrankungen gezeigt. Darüber hinaus erfordert die 
kurze Halbwertszeit von BiTE-Antikörpern eine kontinuierliche intravenöse Infusion und die 
systemische Gabe von BiTE-Antikörpern kann ernsthafte oder sogar tödliche Nebenwirkungen 
verursachen. 
Wir stellen die Hypothese auf, dass die Expression von BiTE-Antikörpern in Krebszellen durch 
das onkolytische Masernvirus die therapeutische Wirksamkeit im Vergleich zu den jeweiligen 
Einzeltherapien verbessert. Des Weiteren nehmen wir an, dass die lokale Expression von BiTE-
Antikörpern die systemische Belastung verringert und dadurch die Sicherheit der BiTE-
Therapie verbessert. Um diese Hypothesen zu überprüfen wurden Masernviren hergestellt, die 
BiTE-Antikörper kodieren (MV-BiTE). Die MV-BiTE-Vektoren wurden in vitro bezüglich 
ihrer Replikationskinetiken, ihrer onkolytischen Aktivität und der BiTE-Antikörper-Expression 
charakterisiert. BiTE-Antikörper, hergestellt von MV-BiTE-infizierten Zellen, wurden 
aufgereinigt, um ihre Bindungsspezifität und die BiTE-vermittelte T-Zell-Zytotoxizität in vitro 
zu untersuchen. Die therapeutische Wirksamkeit von MV-BiTE in Bezug auf die 
Überlebensdauer von Mäusen wurde in syngenen und xenogenen Tumormodellen demonstriert. 
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In allen Studien wurden keine Anzeichen einer MV-BiTE-verursachten Toxizität beobachtet 
und die BiTE-Plasma-Level von MV-BiTE-behandelten Mäusen blieben unterhalb der 
Nachweisgrenze. 
Zusammenfassend kann gesagt werden, dass die Expression von BiTE-Antikörpern in 
Krebszellen durch onkolytische Masernviren realisierbar ist und eine systemische Belastung 
mit BiTE-Antikörpern verringert. Darüber hinaus demonstrierte MV-BiTE therapeutische 
Wirksamkeit in verschiedenen Modellen solider Tumore in vivo. Die MV-BiTE-Konstrukte 
stellen eine modulare Vektor-Plattform dar, die wahlweise an jedes beliebige Tumorantigen 
angepasst werden kann. Dadurch verkörpert die MV-BiTE-Therapie einen vielversprechenden 
Ansatz in der individualisierten Krebs-Immunvirustherapie. 
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1. Introduction 
1.1. Motivation 
In 1971, President Richard Nixon signed the National Cancer Act and thereby declared “war 
on cancer”, which in those times represented a major cause of death worldwide. Back then, 
discovering the cure of cancer did not seem less utopian than President Kennedy’s 
pronouncement in 1961 to land a manned mission on the Moon. While first men set foot on the 
lunar surface in 1969, cancer still remains a leading cause of death with 8.7 million cancer-
related deaths half a century later (1). Statistically, one in three men and one in four women 
will develop cancer during a lifetime (1). Still, the field of cancer research impressively 
developed in the past decades and we are by now able to precociously detect and better control 
some tumor diseases. But chances for cure appear to have no prospect of success in an advanced 
stage of disease or if standard therapy fails. 
1.2. The Immune System and Cancer - a double-edged Sword 
The immune system has the exceptional ability to recognize and clear neoplastic cells which 
eventually could give rise to cancer, a phenomenon known as “cancer immunosurveillance” 
(2). In doing so, cells of the immune system prevail with a remarkable specificity and efficiency, 
which outclasses all anticancer drugs known hitherto. Still, tumorigenesis takes place under the 
surveillance of a fully functional immune system. Perpetual immunological elimination of 
incipient cancer cells may facilitate the emergence of tumor cell variants, which acquired the 
ability to evade or even to counteract the immune system. This process corresponds to the 
broader concept of “cancer immunoediting” which elucidates the ambiguous role of the 
immune system in cancer prevention and progression (3). Cellular and molecular mechanisms 
of immune evasion are well described and immunoevasion was proposed to constitute an 
emerging hallmark of cancer (4, 5). The initiation of a sustained antitumor immune response is 
an iterative process described as the “cancer immunity cycle” (6). The patient’s individual 
cancer immune status may be impaired in one or more steps of this cycle of anticancer 
immunity. Specific manipulations of the immune system to enhance or reinitiate anticancer 
immunity is the main objective of cancer immunotherapy (7, 8). 
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1.3. Cancer Immunotherapy 
1.3.1. A Historical Perspective 
Ancient writings on papyrus report on Imhotep’s – a deified Egyptian chancellor to the pharaoh, 
architect and physician (approximately 2,600 BC) – recommendation to treat swellings 
(tumors) with a poultice followed by incision of the tumor. This procedure causes an infection 
at the tumor site which may result in tumor regression (9). Various rudimentary approaches to 
stimulate the immune system in cancer therapy have been described over thousands of years. 
In the nineteenth century, Dr. William B. Coley, a 28-year-old surgeon in the first year of 
practice, was deeply affected by the death of his first sarcoma patient (10). Coley became 
interested in treatment of sarcomas and digged into historical medical literature. He found many 
physicians to report on spontaneous tumor regressions after coincidental bacterial infections 
(11). Inspired by the medical literature, Coley experimentally developed “Coley’s toxin”, a 
mixture of heat-killed Streptococcus pyogenes and Serratia marcescens. His first sarcoma 
patient treated with Coley’s toxin went into a life-long complete remission and Coley became 
the “father of cancer immunotherapy” (12). 
However, Coley’s toxin and cancer immunotherapy in general were controversially discussed 
in medical science, due to low response rates and a lack of understanding the underlying 
mechanisms. Then, in the 1990s and 2000s some observations aroused attention to the field of 
cancer immunotherapy. Immunodeficient mice were more susceptible to carcinogen-induced 
tumors than wild-type mice (13). Furthermore, tumors were induced in immunodeficient mice 
and transplanted into naïve syngeneic immunocompetent mice. A significant number of mice 
(40 %) rejected tumor transplants derived from immunodeficient mice. In contrast, when 
tumors were induced in immunocompetent mice and transplanted into wild-type mice, no tumor 
rejection was observed (14). These findings directly proved the importance of immunity in 
cancer and revived the field of cancer immunotherapy. 
1.3.2. The Principles of Cancer Immunotherapy 
Cancer immunotherapy comprises various approaches in cancer treatment, which modify 
components of the immune system to enhance or reinitiate a sustained antitumor immune 
response. The initiation of an antitumor immune response is described by Chen and Mellman 
1.3. Cancer Immunotherapy 
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as an iterative process which is effected in seven steps (6): Antigens from dying tumor cells are 
released (step 1). Tumor-specific and -associated antigens (TSAs/TAAs), e.g. derived from 
mutated genes, oncogenic viruses, oncofetal proteins or posttranslationally altered proteins 
(15), are ingested by immature migratory dendritic cells (DCs). Immunogenic cell death and 
proinflammatory cytokines mature DCs into activated immunogenic DCs which present tumor 
antigens on major histocompatibility complex (MHC) class I and II to T cells in lymphoid 
organs (step 2) (16, 17). Antigen-specific T cells are primed and activated by DCs and become 
cytotoxic T lymphocytes (CTLs) (step 3). Next, CTLs leave the lymphoid organs and traffic to 
the tumor site via the blood stream (step 4). At the tumor site, CTLs leave the blood stream and 
infiltrate the tumor, further referred to as tumor-infiltrating lymphocytes (TILs) (step 5). TILs 
recognize the specific tumor antigens on the tumor cells (step 6) and eliminate tumor cells (step 
7). Elimination of tumor cells results in the release of more tumor antigens (step 1). The cancer 
immunity cycle continues which broadens and boosts the antitumor immune response (6). 
However, single or multiple steps in the cycle of anticancer immunity are impaired in cancer 
patients, which hampers the immune system to establish or maintain a sustained antitumor 
immune response. Tumor cells might become unrecognizable for T cell-mediated elimination 
by impaired antigen processing or antigen presentation on MHC class I molecules (18). Immune 
checkpoint molecules e.g. cytotoxic T-lymphocyte-associated protein-4 (CTLA-4, cluster of 
differentiation (CD)152) and programmed cell death-1 (PD-1, CD279) inhibit T cell signaling. 
Tumor cells might express ligands for such immune checkpoint molecules to suppress immune 
function. A variety of immune inhibitory cytokines, e.g. transforming growth factor-β (TGF-
β), vascular endothelial growth factor (VEGF) or indoleamine 2,3-dioxygenase (IDO) can be 
expressed by tumor cells or tumor-associated stromal cells (19). Also immunosuppressive 
leukocytes, such as regulatory T cells, myeloid-derived suppressor cells (MDSCs), 
plasmacytoid DCs (pDCs) and M2 macrophages produce inhibitory cytokines and support 
tumor development (19). Different immunotherapies have been developed to specifically target 
immune escape mechanisms, which might resolve immune blockade and lead to tumor 
remission. However, only few cancer patients seem to benefit from these therapies (20). The 
individual and heterogenic immunological landscape of tumors often requires additional 
immune regulating interventions. It remains a substantial challenge to understand the entirety 
of immune regulation and to identify biomarkers to select for cancer patients who will benefit 
from (most likely combined) cancer immunotherapies (7). 
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1.3.3. Classes of Cancer Immunotherapy 
Modern cancer immunotherapies can generally be classified into “active” and “passive” 
approaches. On the one hand, active immunotherapies directly target the patient’s immune 
system to enhance or reinitiate a potent antitumor immune response. Examples for active 
immunotherapies are: (I) Cytokines: Interleukin (IL)-2, Interferon (IFN)-α2a and IFN-α2b non-
specifically stimulate the patient’s immune system and are approved since the 1990s for 
treatment of multiple solid and hematological malignancies (21). (II) DC-based vaccines: 
Autologous DCs are loaded ex vivo with patient-specific TAAs and are reinfused into the patient 
to prime TAA-specific immune responses (22). Sipuleucel-T, the only licensed DC-based 
therapy, has been approved by the Food and Drug Administration (FDA) for treatment of 
metastatic, castration-resistant prostate cancer in 2010 (23). (III) Immune checkpoint inhibitors: 
Monoclonal antibodies (mAbs) target immunosuppressive receptors on T cells or the cognate 
ligands on antigen-presenting cells (APCs), tumor and stromal cells. Ipilimumab (anti-CTLA-
4 mAb) was the first checkpoint inhibitor to be approved by the FDA for treatment of patients 
with unresectable or metastatic melanoma in 2011 (24). 
On the other hand, passive immune therapeutics directly target tumor cells. Examples for 
passive immunotherapies are: (I) Tumor-targeting mAbs: Therapeutic mAbs are commonly 
applied as anticancer drugs and employ a variety of mechanisms to mediate cytotoxicity (25). 
mAbs can block signaling pathways which are important for tumor growth or survival. Other 
mAbs opsonize malignant cells to induce antibody-dependent cell-mediated cytotoxicity 
(ADCC). Antibody-drug conjugates (ADCs) deliver toxins or radionuclides to tumor cells. 
Rituximab, a CD20-targeting, opsonizing antibody, was the first-in-class tumor-targeting mAb 
to be approved by the FDA in 1997 for the treatment of patients with non-Hodgkin lymphoma 
(NHL) (26). (II) Oncolytic viruses (OVs): OVs derive from non-pathogenic virus strains, which 
preferentially infect and replicate in malignant cells. The direct cytopathic activity is mediated 
by excessive viral replication. OVs can be engineered to encode additional transgenes, such as 
therapeutic antibodies or immunostimulatory cytokines to enhance antitumor efficacy (27). The 
first-in-class oncolytic drug to be approved by the FDA in 2015 is talimogene laherparepvec 
(T-VEC) for the treatment of patients with recurrent, unresectable melanoma (28). (III) 
Adoptive T cell transfer: Autologous TILs or peripheral blood lymphocytes (PBLs) are selected 
based on their tumor-reactive capacities or modified to express genetically engineered T cell 
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receptors (TCRs) or chimeric-antigen receptors (CARs). T cells are expanded ex vivo and 
reinfused into the cancer patient (29). Recently, the first CAR T cell therapy (tisagenlecleucel) 
has been approved by the FDA for treatment of children and young adults with acute 
lymphoblastic leukemia (ALL) (30). 
1.3.4. The Class of Bispecific T Cell Engagers (BiTEs) 
BiTE antibodies are fusion proteins of two, flexibly linked single chain variable fragments 
(scFvs) (Figure 1.1). BiTEs simultaneously bind CD3ε, a component of the T cell co-receptor 
CD3, and any TAA expressed on the tumor cell surface. The short, five amino acids (AAs) 
linker connecting the two scFvs forces T cells into close proximity to tumor cells which in 
combination with T cell engagement via CD3 is sufficient to activate T cells (31). Activated T 
cells form cytolytic synapses which are identical to synapses formed upon regular T cell 
activation (32). CD8+ cytotoxic T cells and CD4+ helper and even regulatory T cells can be 
engaged which induces the expression of activation markers CD69 and CD25 and cytokines 
such as IL-2, IFN-γ, tumor necrosis factor (TNF), granzyme B and perforin (33-38). Thereby, 
BiTE antibodies can induce T cell proliferation and potent, serial tumor cell lysis at 
subpicomolar concentrations or low effector to target cell ratios (36, 37, 39). OKT3, an anti-
CD3 mAb, is known to non-specifically activate T cells by TCR complex-clustering (40). 
However, monovalent CD3-binding by BiTEs is unable to induce T cell activation in the 
absence of tumor cells (37). BiTE-mediated T cell cytotoxicity is independent of proper antigen 
presentation by tumor cells, T cell co-stimulation and TCR specificity (32, 36, 41). Thus, BiTEs 
can engage polyclonal T cells to effectively eliminate tumor cells, which may have evolved 
immune escape mechanisms (42). 
Blinatumomab, a CD19-targeting BiTE, is the first BiTE antibody which has been approved by 
the FDA for treatment of patients with relapsed or refractory (R/R) B cell precursor ALL (43). 
There is a high medical need for treatment options in R/R ALL patients (44). Blinatumomab 
was administered in short intravenous infusions in the initial phase I trials (45). Short terminal 
half-life of approximately 2 h were observed and peak serum levels caused severe toxicity 
which led to early termination of the trials. Step dosing and continuous intravenous infusion of 
blinatumomab reduced toxicities and stabilized blinatumomab plasma levels (46). A phase II 
clinical trial compared blinatumomab (n = 271) with standard of care (SOC) (n = 134). 
1. Introduction 
 
6  
Complete remission rates and median survival for blinatumomab were superior to SOC (46 
versus 28 % and 7.8 versus 4.0 months, respectively) (47). Common grade 3 or higher adverse 
events (AEs) were infections, pyrexia and hematological toxicities (48-51). However, serious 
and even fatal AEs occurred which led to treatment discontinuation in 18 % of the patients, 
including neurotoxicity (43). 
 
Figure 1.1: Representation of the bispecific T cell engager (BiTE) principle. (Left part) 
BiTEs consist of two single chain variable fragments (scFvs): One scFv is always directed 
against the T cell co-receptor CD3 (blue). The second scFv targets a tumor-associated antigen 
(TAA) expressed on the tumor cell surface (red). (Right part) Simultaneous binding of CD3 on 
the T cell and a TAA on the tumor cell activates the T cell and induces the formation of an 
immunological synapse, which results in tumor cell lysis. Adapted from (52). 
 
Various BiTE antibodies for hematological and solid tumors are in preclinical and clinical 
development. Clinically most advanced BiTEs are AMG 110/MT 110 (anti-EpCAM, 
NCT00635596), AMG 211/MEDI-565 (anti-CEA, NCT02291614), AMG 212 (anti-PSMA, 
NCT01723475), BI 836909/AMG 420 (anti-BCMA, NCT02514239), and AMG 330 (anti-
CD33, NCT02520427). All BiTE constructs demonstrate potent antitumor activity in vitro. 
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However, meaningful therapeutic effects with BiTEs targeting solid tumors have not been 
reported so far (53-56). 
Several other T cell and also natural killer (NK) cell engaging antibody formats are currently 
under clinical investigation as anticancer drugs (57, 58). Examples: (I) Dual-affinity re-
targeting (DART) antibodies are diabodies stabilized with an inter-chain disulfide bond (e.g. 
NCT02152956, NCT02248805) (59). (II) TrioMabs are immunoglobulin (Ig)G-like bispecific, 
trifunctional antibodies with a chimeric non-human Fc-region that additionally interacts with 
Fcγ receptor+ accessory cells (e.g. NCT00189345, NCT01569412, NCT01138579) (60). (III) 
Tetravalent, bispecific tandem diabodies (TandAb) were designed to target the NK cell 
activating receptor CD16 and simultaneously the lymphoma antigen CD30 (NCT02321592, 
NCT03192202) (61). 
 
1.4. Oncolytic Viruses as Cancer Immunotherapeutics 
Oncolytic viruses (OVs) are classified as passive immunotherapeutics based on their intrinsic 
antitumor activity (chapter 1.3.3.). On the contrary, OVs can induce potent and lasting tumor-
directed immune responses which in some cases constitute the most detrimental antitumor 
effects (62). Hence, OVs can act as both, passive and active cancer immunotherapeutics. 
According to Chen’s and Mellman’s concept of the cancer immunity cycle, the release of TAAs 
is the basis to induce an antitumor immune response (chapter 1.3.2.). Oncolytic cell death 
releases tumor antigens, which can be ingested by resident and infiltrating DCs. In addition, 
most viruses induce an immunogenic cell death (ICD) (63). The virus-induced ICD provides 
danger signals which recruit more DCs and mature them into potent antigen presenting cells 
(64). Danger signals are viral pathogen-associated molecular patterns (PAMPs; e.g. nucleic 
acids, viral proteins) and damage-associated molecular patterns (DAMPs; e.g. high-mobility 
group box 1 (HMGB1), heat-shock proteins (HSPs), ATP, uric acid). PAMPs and DAMPs are 
recognized by pattern-recognition receptors (PRRs), such as toll-like receptors (TLRs), retinoic 
acid-inducible gene-1 (RIG-1)-like receptors (RLRs) or nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLRs) (65). PRR downstream signaling in the context of an 
acute inflammation induces the release of cytokines which recruit and activate further immune 
1. Introduction 
 
8  
cells in favor of an antitumor immune response (e.g. IL-6, IL-12, IFN-γ, TNF) (62). However, 
viral infections potentially induce antiviral cellular and humoral immune responses as well and 
rapid viral clearance will limit OV efficacy. Several strategies such as natural or engineered 
serotype switching, polymer coating of viral particles, cell carriers or transient host 
immunosuppression have been explored preclinically to protect OVs from premature clearance 
by the immune system (66-73). 
OVs have been genetically modified to augment virus-mediated antitumor immunity by gene 
delivery of immune modulating transgenes (74). Examples: (I) Local expression of cytokines 
such as IL-2 (75), IL-12 (76), IFN-β (77) or granulocyte macrophage colony-stimulating factor 
(GM-CSF) (78) has demonstrated enhanced therapeutic antitumor efficacy. (II) TAA release 
and presentation by DCs after oncolysis can be considered an in situ vaccination. OVs encoding 
TAAs can boost the oncolytic vaccination effects and enhance antitumor immune responses 
(79-84). (III) Immune checkpoint inhibitory (ICI) antibodies have demonstrated significant 
clinical success in the treatment of several solid tumor entities (85). However, efficacy of ICI 
antibodies depends on an existing antitumor immune response and vice versa OV efficacy can 
be limited by immune checkpoints. Not unexpectedly, synergistic effects of ICI antibodies and 
OVs have been described and ICI antibody-encoding OVs have been developed (86-94). 
1.4.1. Clinical Applications of Immune Modulator-Encoding OVs 
The clinically most advanced OV encoding an immune modulator is T-VEC, an oncolytic 
herpes simplex virus (HSV) encoding GM-CSF. T-VEC has been approved by the FDA in 2015 
for the treatment of patients with recurrent, unresectable melanoma (chapter 1.3.3.). A phase 
III trial compared treatment of melanoma patients with T-VEC (n = 295) to subcutaneous GM-
CSF (n = 141). T-VEC was generally well tolerated and the durable response rate (DRR) and 
overall survival (OS) were significantly improved compared to the control arm (DRR: 16.3 % 
versus 2.1 %; OS: 23.3 versus 18.9 months) (95). Forty-seven % of injected lesions completely 
resolved. However, complete resolution of only 22 % of uninjected non-visceral lesions and 9 
% of uninjected visceral lesions was achieved, suggesting that systemic antitumor immunity 
could be improved by combination with other systemically active immunotherapeutic drugs 
(96). Currently, T-VEC and different combinations with ICI antibodies or chemotherapeutics 
are under investigation for the treatment of melanoma (NCT01740297, NCT02263508, 
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NCT02366195) (93, 94, 97), breast cancer (NCT02658812, NCT02779855), head and neck 
cancer (NCT02626000), hepatocellular carcinoma and liver metastasis (NCT02509507), 
lymphoma (NCT02978625) and sarcoma (NCT02453191, NCT02923778). Other OVs 
encoding GM-CSF are currently under clinical development (JX-594, vaccinia virus (VV), 
NCT02630368, NCT02562755, NCT02977156; Oncos-102 and CG0070, oncolytic 
adenoviruses (oAd), NCT03003676, NCT02879669, NCT02963831, NCT02365818). Further 
OVs encoding immune modulators under clinical investigation are: VSV-IFNβ-NIS, a vesicular 
stomatitis virus encoding IFN-β and a sodium/iodide symporter (NIS) (NCT03017820, 
NCT02923466); PROSTVAC, a VV encoding the TAA prostate-specific antigen (PSA) and 
three immune costimulatory molecules (NCT02933255, NCT02326805, NCT02649439, 
NCT02772562, NCT02506114, NCT01145508, NCT02649855, NCT00450463, 
NCT02153918, NCT01867333, NCT01875250, NCT01322490); Ad5-yCD/mutTKSR39rep-
hIL12, an oAd encoding IL-12 for treatment of patients with locally recurrent prostate cancer 
after radiotherapy (NCT02555397); MG1MA3, a heterologous virus prime-boost vaccination 
strategy with a non-replicating adenovirus encoding melanoma-associated antigen 3 (MAGE-
A3) (AdMA3, prime) and an oncolytic maraba virus encoding the same TAA (MG1MA3, 
boost) (NCT02285816, NCT02879760). 
1.4.2. Oncolytic Viruses encoding Bispecific T Cell Engagers (OV-BiTEs) 
OVs have direct antitumor activity and the potential to reinitiate or enhance a preexisting 
antitumor immune response (chapter 1.3.3 and chapter 1.4.). However, physical and chemical 
barriers within the tumor microenvironment (TME), such as dense extracellular matrices, areas 
of necrosis, intratumoral stromal cells, hypoxic conditions, low extracellular pH or elevated 
interstitial pressure can limit viral infection, spread and oncolytic efficacy (98, 99). 
Furthermore, tumor cells can evade an OV-mediated antitumor immune response by a variety 
of immune escape mechanisms (chapter 1.3.2.). On the contrary, BiTEs employ existing 
polyclonal T cells and mediate tumor-specific immune activation, even against tumor cells, 
which have evolved immune escape mechanisms (chapter 1.3.4.). However, serious and even 
fatal AEs can occur after continuous intravenous infusion, which is required to maintain 
therapeutic plasma levels. Furthermore, BiTEs have not yet proven to be effective against solid 
tumors. For solid tumors, a sufficient T cell density by preexisting or infiltrating T cells has to 
be given. After systemic application, BiTEs have to reach and penetrate the tumor, which is in 
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principle feasible as demonstrated in a mouse study with radionuclide-labeled anti-EpCAM 
BiTE (100). However, the implanted tumor cell lines homogeneously expressed EpCAM, while 
target antigen expression in cancer patients might be heterogeneous or negatively selected. 
These factors provide a strong rationale, that tumor-targeted BiTE expression by OV delivery 
can overcome some major limitations of either monotherapy alone. Interestingly, BiTEs could 
even engage antiviral CTLs to direct them against tumor cells, which might be valuable in 
preventing premature viral clearance by the immune system. The concept of OV-BiTE mode 
of action in the context of the cancer immunity cycle is illustrated in Figure 1.2. 
Figure 1.2: OV-BiTE in the cancer immunity cycle. Virus-induced immunogenic cell death 
releases tumor antigens (red dots) and pro-inflammatory cytokines (green triangles) (step 1). 
Tumor antigens, danger signals and cytokines are central for DC maturation. Mature DCs are 
potent antigen presenting cells, secrete further cytokines and activate T cells in tumor draining 
lymph nodes (steps 2+3). Cytotoxic T lymphocytes (CTLs) infiltrate into tumors (steps 4+5). 
Tumor infiltrating lymphocytes (TILs) recognize and eliminate tumor cells (step 6). 
Furthermore, BiTEs produced by OV-infected tumor cells engage polyclonal resident and 
infiltrating tumor antigen-specific T cells to eliminate tumor cells, independent of antigen 
presentation and co-stimulatory signals (step 7). Adapted from (6). 
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The potential of oncolytic viruses encoding bispecific T cell engagers (OV-BiTEs) has been 
investigated preclinically. The first report on OV-BiTEs was a vaccinia virus encoding an anti-
EphA2 BiTE (VV-EphA2-BiTE) (101). VV-EphA2-BiTE induced T cell activation by means 
of IFN-γ and IL-2 production in vitro and in vivo. IL-2 production was not sufficient to induce 
T cell proliferation. However, T cell proliferation could be induced by additional 
supplementation of the culture medium with 100 U/ml human IL-2. Furthermore, VV-EphA2-
BiTE was evaluated in preventing tumor growth in subcutaneous and lung colonization 
xenograft models by VV-EphA2-BiTE and peripheral blood mononuclear cell (PBMC) 
injections before tumor establishment. 
More recently, Fajardo et al. reported on an oncolytic adenovirus encoding an EGFR-targeting 
BiTE (oAd-EGFR-BiTE) (102). oAd-EGFR-BiTE mediated T cell activation and induced T 
cell proliferation in vitro. Luciferase-expressing T cells were intravenously injected after oAd-
EGFR-BiTE treatment of a subcutaneous xenograft model. Fajardo et al. observed significant 
T cell infiltration into the tumor by in vivo bioluminescence imaging, compared to mice treated 
with unmodified oAd. Both, intratumoral and intravenous injections of oAd-EGFR-BiTE 
demonstrated improved therapeutic efficacy in a subcutaneous xenograft model with the 
transfer of PBMCs. 
A second BiTE-encoding oAd was recently reported by Freedman et al. (oAd-EpCAM-BiTE) 
(103). Peritoneal ascites and pleural effusions from chemotherapy‐pretreated patients with 
different malignancies were inoculated with oAd-EpCAM-BiTE. Autologous T cells within the 
patient samples were activated and efficiently directed to primary human tumor cells ex vivo. 
Ascites or pleural fluids from some patients were immunosuppressive and significantly 
attenuated T cell activation and degranulation of PBMC-derived T cells by anti-CD3/CD28 
bead activation. Interestingly, attenuated T cell functions were not observed in the presence of 
EpCAM-BiTE, demonstrating the potential of BiTEs to activate T cells in an 
immunosuppressive environment. 
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1.5. Measles Virus 
1.5.1. Measles Virus Biology 
Measles viruses (MVs) are single-stranded, negative sense RNA viruses of the Morbillivirus 
genus within the family of Paramyxoviridae. The enveloped, pleomorphic virion contains a 
non-segmented, ~16,000 nucleotides RNA genome which encodes for six structural (N, P, M, 
F, H and L) and two non-structural proteins (C and V). A schematic of the MV virion and MV 
genome structure is illustrated in Figure 1.3. The six transcription units are separated by non-
transcribed intergenic sequences of three nucleotides and the genome is flanked by 
extracistronic regions at the 3′ (leader) and 5′ (trailer) ends. Leader and trailer sequences are 
essential for viral replication and mRNA transcription (104). The envelope is a host cell-derived 
lipid bilayer and contains the membrane-associated matrix (M) protein, lining the interior of 
the virion, and two transmembrane glycoproteins, fusion (F) and hemagglutinin (H) protein. 
The glycoprotein H forms dimers of homodimers (tetramers) and contains the receptor-binding 
domain, which determines cellular tropism. H protein tetramers form oligomeric complexes 
with trimeric F proteins. H protein receptor engagement induces H and F dissociation and a 
conformational change in F, which mediates MV-host cell membrane fusion (105). Basolateral 
expression of F and H facilitates cell-to-cell fusion and results in syncytia formation in vitro 
and in vivo (106, 107). The M protein interacts with the cytoplasmic tails of the F and H 
glycoproteins and modulates their fusogenic capacity (108, 109). M protein also localizes to the 
host cell nucleus and Yu et al. recently demonstrated that M inhibits host cell transcription by 
binding to nuclear factors (110). Furthermore, M protein is in contact with the ribonucleoprotein 
complex (RNP) and thereby plays a crucial role in assembly of viral progeny (111). The helical 
RNP is a complex of the encapsidated RNA genome and the RNA polymerase. Each 
nucleocapsid (N) protein binds six nucleotides of the viral genome and the ribonucleocapsid is 
required as template for transcription and replication. Thus, it is necessary that the total number 
of nucleotides of the MV genome is a multiple of six, referred to as “the rule of six” (112). The 
ribonucleocapsid is associated with the viral RNA-dependent RNA polymerase, which consists 
of the phosphoprotein (P), a polymerase co-factor, and the large polymerase protein (L). The P 
open reading frame (ORF) additionally encodes two non-structural proteins, C and V. C protein 
is encoded by the P mRNA but translation is initiated 19 nucleotides downstream of the P 
translation initiator methionine. V has an altered reading frame by RNA editing, which produces 
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an alternative C-terminal domain. P, C and V modulate the cellular IFN response to suppress 
antiviral defense mechanisms and to enhance viral replication (113). 
Figure 1.3: Schematic representation of the MV virion and MV genome. (Upper part) The 
measles virus particle is enveloped by a host cell-derived lipid bilayer (green). The matrix 
protein (blue) lines the interior of the virion and is in contact with the nucleocapsid (orange) 
and the luminal tails of the transmembrane glycoproteins, fusion (brown, trimeric) and 
hemagglutinin (grey, tetrameric). The polymerase (purple) and phosphoprotein (red) are 
associated with the nucleocapsid. The nucleocapsid consists of nucleocapsid proteins and 
encapsidates the viral RNA genome. (Lower part) Schematic of MV genome structure. 
 
MV is directly transmitted by airborne spread, therefore extremely contagious and exclusively 
endemic to humans (114). However, MV is phylogenetically closest related to rinderpest virus 
(RPV), an eradicated pathogen of cattle (115). MV could be derived from RPV by adaptation 
to humans or MV and RPV have a common, zoonotic ancestor (116). Cellular receptors for H 
homodimers of MV include signaling lymphocytic activation molecule family member 1 
(SLAMF1) (117), CD46 (118, 119) and nectin cell adhesion molecule 4 (nectin-4) (120, 121). 
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The route of infection occurs via the respiratory tract. MV H binds to CD209 on alveolar 
macrophages and DCs, which induces translocation of intracellular SLAMF1 to the cell surface 
and enables virus entry (122, 123). Infected DCs travel to draining lymphoid organs where T 
and B cells are infected by transmission. The virus amplifies and disseminates to secondary 
lymphoid organs, resulting in severe immunosuppression. During late infection, MV-infected 
lymphocytes in the respiratory tract transmit MV to epithelial cells via nectin-4 on the 
basolateral surface (113). MV progeny is released from the apical surface into the luminal side 
where it can exit the host’s respiratory tract to infect other individuals (124). MV-induced 
immunosuppression is responsible for high rates of mortality through opportunistic infections 
such as pneumonia or diarrhea. Routine use of measles vaccination for infants prevented an 
estimated 20.3 million deaths during 2000-2015 (125). However, the World Health 
Organization (WHO) still estimated 134,200 measles-related deaths in 2015, mainly in 
unvaccinated communities or in regions with inadequate medical care (125). 
 
1.5.2. Oncolytic Measles Viruses 
MV was first isolated in 1954 in Ender’s laboratory from a 13-year-old boy, David Edmonston 
(126). Most attenuated MV laboratory and vaccine strains including Zagreb, AIK-C, Schwarz, 
Moraten and Edmonston B are derived from the Edmonston isolate by propagation in human 
and avian culture systems (127, 128). The first live, attenuated MV vaccine (Edmonston 
B/Rubeovax) was licensed in 1963 in the USA. More attenuated, live vaccines were licensed 
in 1965 (Schwarz) and 1968 (Moraten), which remained protective in 50 years of clinical use 
(114). In 1971, natural MV infections of patients suffering from Burkitt’s lymphoma, 
Hodgkin’s disease and leukemia were reported to coincide with tumor regression and remission 
(129-132). However, interest in using MV vaccine strains as oncolytic therapeutics only 
increased in the 1990’s and early 2000’s, with a profound understanding of MV biology, MV 
genomic sequencing data (133), excellent MV vaccination safety records (134), the ability to 
genetically modify and rescue recombinant MVs (135), promising preclinical data (136-139), 
and a general increasing interest in the use of oncolytic viruses (140). 
The H proteins of wild-type MV and MV vaccine strains have a high affinity to SLAMF1. 
However, predominantly MV vaccine strains also engage CD46 by one or more amino acid 
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exchanges in the H protein (141-143). CD46 is a complement regulator, which protects normal 
cells from damage by activated complement and is therefore ubiquitously expressed (144). In 
the context of cancer, CD46 is frequently overexpressed presumably to effectively protect 
tumor cells from complement-mediated lysis (145). Interestingly, surface density of CD46 
positively correlates with MV entry and syncytia formation, which aids intercellular viral 
spread and enhances viral gene expression (146). Oncolytic MVs have been genetically 
engineered to modify MV tropism, monitor viral replication and kinetics in vivo, augment 
antitumor activity and to evade host antiviral immunity (147). Insertion of large transgenes 
(>6,000 nucleotides) in additional transcription units (ATUs) is feasible and transgenes are 
stably maintained in vitro and in vivo (148, 149). 
Encouraging results from clinical trials with cutaneous T cell lymphoma (150) and ovarian 
cancer (151, 152) led to the recruitment of patients for further clinical studies, including 
multiple myeloma (NCT00450814, NCT02192775), ovarian cancer (NCT02068794), head and 
neck cancer (NCT01846091), glioblastoma multiforme (NCT00390299) and pleural 
mesothelioma (NCT01503177). No acquired drug resistance or dose limiting toxicities have 
been observed so far (153). 
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2. Aims and Objectives of the Study 
The main purpose of this study is to provide proof of concept for therapeutic efficacy of 
oncolytic measles viruses encoding bispecific T cell engagers (MV-BiTE). Oncolytic MVs 
have been recognized as potent immunostimulatory anticancer agents. On the one hand, the 
immunogenic cell death of MV-infected tumor cells provides the release of tumor-associated 
antigens, which can be ingested by antigen-presenting cells (APCs) to prime an adaptive 
antitumor immune response. Besides tumor debulking, viral infection causes an inflammatory 
reaction with the release of cytokines and danger- and damage-associated molecular patterns, 
which further recruits and activates immune cells. On the other hand, BiTEs simultaneously 
bind T cells via CD3 and tumor cells via tumor-specific or tumor-associated antigens. 
Consequently, BiTEs activate T cells and selectively direct T cells to lyse tumor cells. Of 
advantage, BiTE-mediated T cell cytotoxicity is independent of T cell receptor specificity, 
antigen presentation by the tumor cells or T cell co-stimulation. Thus, BiTE therapy can 
circumvent some of the mechanisms evolved by tumor cells to escape an immune response. 
BiTEs lack the Fc-region and are small-format antibodies, which is advantageous in terms of 
tissue distribution. However, BiTEs have a short serum half-life and need to be administered 
continuously via infusion pumps. Moreover, systemic administration of BiTEs can cause severe 
side effects. In addition, BiTEs have failed to demonstrate meaningful therapeutic effects 
against solid tumors so far. 
We hypothesize, that tumor-targeted expression of BiTEs by oncolytic MVs enhances 
therapeutic efficacy against solid tumors, as compared to either monotherapy alone. 
Furthermore, we hypothesize that tumor-restricted BiTE expression reduces systemic exposure 
to BiTEs and thus increases the safety profile of BiTE therapy. The concept of MV-BiTE 
therapy is illustrated in Figure 2.1. 
The study objectives include: 
1. To generate measles viruses encoding bispecific T cell engagers (MV-BiTE); 
2. To characterize replication capacity and oncolytic activity of MV-BiTE; 
3. To characterize BiTEs secreted by MV-BiTE-infected cells in terms of binding 
specificity and the ability to mediate T cell cytotoxicity; 
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4. To assess therapeutic efficacy in immunocompetent mice, to analyze tumor-infiltrating 
lymphocytes and to evaluate BiTE plasma levels after MV-BiTE treatment; 
5. To assess therapeutic efficacy in xenografts of patient-derived colorectal cancer 
spheroids with the transfer of human PBMCs and to evaluate BiTE plasma levels after 
MV-BiTE treatment. 
 
Figure 2.1: The concept of oncolytic measles viruses encoding bispecific T cell engagers 
(MV-BiTE). MV-BiTE preferentially infects and replicates in tumor cells. During viral 
replication, BiTEs are expressed and secreted by MV-BiTE-infected tumor cells. The oncolytic 
activity of MV infection is mediated by viral replication and the formation of large, 
multinucleated syncytia. As a bystander effect, secreted BiTEs simultaneously engage T cells 
and tumor cells and thus mediate tumor-specific T cell cytotoxicity. 
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3. Materials and Methods 
3.1. Materials 
3.1.1. Chemicals 
Reagent Company Catalog 
Antibiotic-antimycotic (ABAM) (100x) Sigma-Aldrich A5955 
Agarose, molecular biology grade Sigma-Aldrich A9539 
DAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich D8417 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D2438 
DNA gel loading dye (6x) (bromophenol 
blue, xylene cyanol FF and glycerin) 
Thermo Fisher Scientific R0611 
Ethidium bromide, 0.07 % 1239-45-8 AppliChem 
Ethylenediaminetetraacetic acid (EDTA) 
salt solution 
Sigma-Aldrich E7889-100ML 
Glycerol Sigma-Aldrich G7757-1L 
Imidazole, >99 % Sigma-Aldrich I5513-25G 
Kanamycin Sigma-Aldrich K0129 
Methanol, > 99.9 % Carl-Roth 8388.1 
Penicillin-Streptomycin,  Thermo Fisher Scientific 15070063 
Skim milk powder, blotting grade Carl-Roth T145.2 
Sodium chloride (NaCl), >99.5 % Carl-Roth 3957.3 
Hydrochloric acid (HCl), 37 % Carl-Roth 4625.1 
Sodium hydroxide (NaOH), 50 % Carl-Roth 8655.1 
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3.1.2. Buffers 
Buffer Company Catalog 
Dulbecco's Phosphate-Buffered Saline (D-
PBS) without calcium and magnesium 
Thermo Fisher Scientific 14190250 
Ammonium-Chloride-Potassium (ACK) 
lysing buffer 
Thermo Fisher Scientific A1049201 
Laemmli buffer (4x) Bio-Rad 61-0747 
Novex Tris-Glycine transfer buffer (25x) Thermo Fisher Scientific LC3675 
Rotiphorese SDS-PAGE running buffer (10x) Carl-Roth 3060.1 
Tris/Borate/EDTA (TBE) Genaxxon bioscience M3206.1000 
Roti-Stock Tris-Buffered Saline-Tween (TBS-
T) (10x) 
Carl-Roth 1061.1 
2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) (1 M) 
Thermo Fisher Scientific 15630080 
RIPA Lysis and Extraction Buffer Thermo Fisher Scientific   89900 
 
3.1.3. Growth Medium for Bacteria and Cell Culture 
Medium Company Catalog 
Dulbecco's Modifed Eagle Medium (DMEM) Thermo Fisher Scientific 61965026 
LB (Lysogeny Broth) medium Carl-Roth X964.1 
Opti-MEM Thermo Fisher Scientific 51985034 
Roswell Park Memorial Institute medium 
1640 (RPMI 1640)  
Thermo Fisher Scientific 61870044 
SOC outgrowth medium (Super Optimal 
broth with Catabolite repression) 
New England Biolabs B9020S 
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OptiPRO SFM (Serum-Free Medium) Thermo Fisher Scientific 12309019 
 
3.1.4. Oligonucleotides 
Name Sequence 5‘  3‘ TA [°C] 
Amp-1 forward CCCCGAAGAACGTTTTC 53 
Amp-2 reverse TCGTCGTTTGGTATGGC 50 
CMVP-94 forward CAAAATGTCGTAACAACTCCGC 58 
ColE-1 forward CGGTAACTATCGTCTTGAGTCC 60 
ColE-2 reverse GTGCCTCACTGATTAAGCATTGG 61 
eGFP-AscI reverse TTTGGCGCGCCTTACTTGTACAGCT 55 
hCD3 forward  CGTCAAGATGTCCTGCAAAG 55 
His-tag_BiTE 
reverse 
GTGGTGATGATGGTGGTGAG 56 
Igκ-leader_BiTE 
forward 
GGTACTGCTGCTCTGGGTTC 55 
IRES-104 reverse CCTCACATTGCCAAAAGACG 57 
mCD3 forward GTGCAACCAGGCAAATCTCT 55 
MeV H-9018 
forward 
GTGTGCTTGCGGACTCAGAATC 62 
MeV L-9249 reverse CAGATAGCGAGTCCATAACGG 60 
MluI-eGFP forward TTACGCGTCGCCACCATG 55 
pCG forward TTGTGCTGTCTCATCATTTTG 56 
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pCG reverse GTCCCCATAATTTTTGGCAG 56 
pCG-MCSa_b 
forward 
GGACGTGGTTTTCCTTTGAA 55 
pJET 1.2 forward CGACTCACTATAGGGAGAGCGGC 66 
pJET 1.2 reverse AAGAACATCGATTTTCCATGGCAG 59 
pUC forward GCCAGGGTTTTCCCAGTCACGA 64 
pUC reverse GAGCGGATAACAATTTCACACAGG 61 
scFv_aCEA_SfoI 
forward 
CCCTTTGGCGCCCAGGTGAAACTGC 60 
scFv_aCEA reverse TGATGGTGATGGTGATGAGAACCTCTTGC 60 
scFv_hCD20_SfoI 
forward 
TTTGGCGCCCAGGTTCAGCTGGTCCAGTCAGG 69 
scFv_hCD20_SfoI 
reverse 
TGGTGATGGTGATGAGAACC 55 
wPRE reverse CATTAAAGCAGCGTATCCACATAGC 61 
 
3.1.5. DNA Plasmids 
Name Description 
pEX-A2-anti-mouse 
CD3-scFv 
Cloning vector encoding a mouse CD3 targeting scFv with 
codon optimization (GENEius; Biolink 
Informationstechnologie, Martinsried) for expression in 
murine cells (Eurons MWG) 
pUC29 Cloning vector, identical to pUC19 (154) except for expanded 
multiple cloning site 
pJET 1.2 Cloning vector, GenBank: EF694056.1 
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pcDI dsRed Eukaryotic expression vector for a variant of the Discosoma red 
fluorescent protein 
pCG Eukaryotic expression vector with a CMV promotor and a 
multiple cloning site (155) 
pCG L Eukaryotic expression vector encoding MV L (Edmonston B 
vaccine strain) 
pCG N 
 
Eukaryotic expression vector encoding MV N (Edmonston B 
vaccine strain) 
pCG NSe Hbl-αCEA  
 
Eukaryotic expression vector encoding MV H (Edmonston B 
vaccine strain), which is “blinded” for binding to CD46 and 
CD150 with Y481, R533A, S548L and F549S mutations and 
fused to a single chain antibody against human CEA with a 
hexa histidine tag at the C terminus 
pCG P 
 
Eukaryotic expression vector encoding MV P (Edmonston B 
vaccine strain) 
pcpNSe H-ATU MV (Edmonston B vaccine strain) antigenome with an 
additional transcription unit downstream of the H ORF; allows 
for rescue using the RNA polymerase II system 
pcpNSe H-hCD3xCD20 MV (Edmonston B vaccine strain) antigenome encoding a 
BiTE antibody targeting human CD3 and human CD20 
downstream of the H ORF; allows for rescue using the RNA 
polymerase II system 
pcpNSe H-hCD3xCEA MV (Edmonston B vaccine strain) antigenome encoding a 
BiTE antibody targeting human CD3 and human CEA 
downstream of the H ORF; allows for rescue using the RNA 
polymerase II system 
pcpNSe H-mCD3xCD20 MV (Edmonston B vaccine strain) antigenome encoding a 
BiTE antibody targeting murine CD3 and human CD20 
downstream of the H ORF; allows for rescue using the RNA 
polymerase II system 
pcpNSe H-mCD3xCEA MV (Edmonston B vaccine strain) antigenome encoding a 
BiTE antibody targeting murine CD3 and human CEA 
downstream of the H ORF; allows for rescue using the RNA 
polymerase II system 
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pcpNSe leader-eGFP H-
ATU 
MV (Edmonston B vaccine strain) antigenome with the eGFP 
ORF upstream of the N ORF and an additional transcription 
unit downstream of the H ORF; allows for rescue using the 
RNA polymerase II system 
pcpNSe leader-eGFP H-
hCD3xCD20 
MV (Edmonston B vaccine strain) antigenome with the eGFP 
ORF upstream of the N ORF and encoding a BiTE antibody 
targeting human CD3 and human CD20 downstream of the H 
ORF; allows for rescue using the RNA polymerase II system 
pcpNSe leader-eGFP H-
hCD3xCEA 
MV (Edmonston B vaccine strain) antigenome with the eGFP 
ORF upstream of the N ORF and encoding a BiTE antibody 
targeting human CD3 and human CEA downstream of the H 
ORF; allows for rescue using the RNA polymerase II system 
pcpNSe leader-eGFP H-
mCD3xCD20 
MV (Edmonston B vaccine strain) antigenome with the eGFP 
ORF upstream of the N ORF and encoding a BiTE antibody 
targeting murine CD3 and human CD20 downstream of the H 
ORF; allows for rescue using the RNA polymerase II system 
pcpNSe leader-eGFP H-
mCD3xCEA 
MV (Edmonston B vaccine strain) antigenome with the eGFP 
ORF upstream of the N ORF and encoding a BiTE antibody 
targeting murine CD3 and human CEA downstream of the H 
ORF; allows for rescue using the RNA polymerase II system 
 
3.1.6. Restriction Enzymes 
Enzyme Conditions Company Catalog 
AscI CutSmart New England Biolabs R0558 
BamHI Roche B Roche 10798975001 
BstZI Eco52I-buffer Thermo Fisher Scientific ER0331 
EcoRI Roche H Roche 10703737001 
HindIII NEB2.1 New England Biolabs R0104   
MauBI Tango Thermo Fisher Scientific ER2081 
MluI NEB3.1 New England Biolabs R0198 
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NdeI CutSmart   New England Biolabs R0111   
NheI-HF CutSmart New England Biolabs R3131   
NotI-HF CutSmart New England Biolabs R3189 
PacI CutSmart New England Biolabs R0547   
PvuII CutSmart New England Biolabs R0151 
SalI-HF CutSmart New England Biolabs R3138   
SbfI CutSmart New England Biolabs R0642 
ScaI-HF CutSmart New England Biolabs R3122 
SfoI CutSmart New England Biolabs R0606 
SpeI CutSmart New England Biolabs R0133 
XbaI CutSmart New England Biolabs R0145   
 
3.1.7. Antibodies 
Antibody Description Company Catalog 
α-β-actin-Peroxidase murine IgG1, 1:20,000 
clone AC-15 
Sigma-Aldrich A3854 
α-HA mouse IgG1, κ, 1:10,000, 
clone HA-7 
Sigma-Aldrich H9658 
α-HA-biotin rat IgG1, κ, 1:500, 
clone 3F10 
Sigma-Aldrich 12158167001 
α-HA-PE mouse IgG1κ, 1:11, 
clone GG8-1F3.3.1 
Miltenyi Biotec 130-092-257 
α-His-FITC mouse IgG1, κ, 1:10, 
clone 13/45/31-2 
Dianova DIA 920 
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α-human CD46-PE mouse IgG1, κ, 1:100, 
clone TRA-2-10 
BioLegend 352401 
α-human CEA-PE mouse IgG1, κ, 1:11, 
clone CB30 
abcam ab42796 
α-mouse CD3-PerCP-
Cy5.5 
rat IgG2b, κ, 1:100, 
clone 17A2 
BD Biosciences 560527 
α-mouse CD4-APC-Cy7 rat IgG2b, κ, 1:100, 
clone GK1.5 
BD Biosciences 561830 
α-mouse CD8a-APC rat IgG2a, κ, 1:100, 
clone 53-6.7 
BD Biosciences 561093 
α-mouse CD25-PE-Cy7 rat IgG1, κ, 1:100, 
clone PC61 
BD Biosciences 561780 
α-mouse CD69-PE Armenian hamster IgG, 
1:100, clone H1.2F3 
BioLegend 104507 
α-mouse CD16/CD32 (Fc 
block) 
rat IgG2b, κ, 1: 100, 
clone 2.4G2 
BD Biosciences 553141 
α-mouse IgG-HRP rabbit polyclonal, 
1:2,000 
Bethyl A90-217P 
Armenian hamster IgG-
PE 
isotype control, 1:100, 
clone HTK888 
BioLegend 400907 
mouse IgG1, κ-PE isotype control, 1:11, 
clone MOPC-21 
BD Biosciences 555749 
mouse IgG1, κ-FITC isotype control, 1:10, 
clone X40 
BD Biosciences 345815 
rat IgG2a, κ-APC isotype control, 1:100, 
clone R35-95 
BD Biosciences 553932 
 
rat IgG2b, κ-APC-Cy7 isotype control, 1:100, 
clone A95-1 
BD Biosciences 552773 
rat IgG2b, κ-PerCP-Cy5.5 isotype control, 1:100, 
clone A95-1 
BD Biosciences 550764 
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3.1.8. Cell cultures 
Cell culture Description Medium Source 
B16 Murine melanoma cell line 
derived from a spontaneous 
tumor of a C57BL/6 mouse 
RPMI + 10 % FCS D. M. 
Nettelbeck, 
Heidelberg, 
Germany 
B16-CD20 B16 cells transduced with a 
lentiviral vector for stable 
expression of human CD20 
RPMI + 10 % FCS C. E. 
Engeland, 
Heidelberg, 
Germany 
B16-CD20-CD46 B16 cells transduced with a 
lentiviral vector for stable 
expression of human CD20 
and human 46 
RPMI + 10 % FCS B. Hoyler, 
Heidelberg, 
Germany 
MC38 Murine colon 
adenocarcinoma cell line 
derived from a chemically 
induced tumor in a C57BL/6 
mouse 
DMEM + 10 % FCS R. Cattaneo, 
Rochester, 
MN 
MC38-CEA MC38 cells transduced with 
a lentiviral vector for stable 
expression of human CEA 
variant 
DMEM + 10 % FCS R. Cattaneo, 
Rochester, 
MN 
MC38-CEA-CD46 MC38 cells transduced with 
a lentiviral vector for stable 
expression of human CEA 
variant and human 46 
DMEM + 10 % FCS B. Hoyler, 
Heidelberg, 
Germany 
TSC8 Primary human colorectal 
cancer tissue or derived 
metastases 
Advanced DMEM/F-12 
+ 0.6 % glucose, 1 % 
penicillin/streptomycin, 
2 mM L-glutamine, 4 
µg/ml heparin, 5 mM 
HEPES, 4 mg/ml BSA, 
10 ng/ml FGF basic, 20 
ng/ml EGF 
University 
Hospital 
Heidelberg 
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TSC17 Primary human colorectal 
cancer tissue or derived 
metastases 
Advanced DMEM/F-12 
+ 0.6 % glucose, 1 % 
penicillin/streptomycin, 
2 mM L-glutamine, 4 
µg/ml heparin, 5 mM 
HEPES, 4 mg/ml BSA, 
10 ng/ml FGF basic, 20 
ng/ml EGF 
University 
Hospital 
Heidelberg 
TSC23 Primary human colorectal 
cancer tissue or derived 
metastases 
Advanced DMEM/F-12 
+ 0.6 % glucose, 1 % 
penicillin/streptomycin, 
2 mM L-glutamine, 4 
µg/ml heparin, 5 mM 
HEPES, 4 mg/ml BSA, 
10 ng/ml FGF basic, 20 
ng/ml EGF 
University 
Hospital 
Heidelberg 
Vero African green monkey 
Cercopithecus aethiops 
kidney epithelial cell line 
DMEM + 10 % FCS ATCC, 
Manassas, 
VA 
 
3.1.9. Recombinant Viruses 
Virus Description 
MV MV derived from the Edmonston B vaccine strain 
MV-eGFP-hCD3xCD20 MV derived from the Edmonston B vaccine strain encoding 
eGFP downstream of the N ORF and a BiTE antibody against 
human CD3 and human CD20 downstream of the H ORF 
MV-eGFP-hCD3xCEA MV derived from the Edmonston B vaccine strain encoding 
eGFP downstream of the N ORF and a BiTE antibody against 
human CD3 and human CEA downstream of the H ORF 
MV-eGFP-mCD3xCD20 MV derived from the Edmonston B vaccine strain encoding 
eGFP downstream of the N ORF and a BiTE antibody against 
murine CD3 and human CD20 downstream of the H ORF 
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MV-eGFP-mCD3xCEA MV derived from the Edmonston B vaccine strain encoding 
eGFP downstream of the N ORF and a BiTE antibody against 
murine CD3 and human CEA downstream of the H ORF 
MV-hCD3xCD20 MV derived from the Edmonston B vaccine strain encoding a 
BiTE antibody against human CD3 and human CD20 
downstream of the H ORF 
MV-hCD3xCEA MV derived from the Edmonston B vaccine strain encoding a 
BiTE antibody against human CD3 and human CEA 
downstream of the H ORF 
MV-mCD3xCD20 MV derived from the Edmonston B vaccine strain encoding a 
BiTE antibody against murine CD3 and human CD20 
downstream of the H ORF 
MV-mCD3xCEA MV derived from the Edmonston B vaccine strain encoding a 
BiTE antibody against murine CD3 and human CEA 
downstream of the H ORF 
 
3.2. Methods 
3.2.1. DNA and RNA Molecular Biology Methods 
Polymerase Chain Reaction 
DNA fragments were amplified for cloning or detection of particular DNA sequences by 
polymerase chain reactions (PCRs). For detection purposes, DNA fragments were amplified 
using 0.6 U OneTaq DNA polymerase (NEB, M0480L), 1x OneTaq standard reaction buffer 
(NEB, M0480), 200 µM deoxynucleotide triphosphate (dNTP) mix (Thermo Fisher Scientific, 
R0192), 500 nM of the respective forward and reverse primers (chapter 3.1.4) and up to 1 µg 
template DNA. The final volume was adjusted to 25 µl with nuclease-free water.  For cloning, 
DNA fragments were amplified using 0.4 U Phusion High-Fidelity DNA Polymerase (NEB, 
M0530), 1x Phusion HF buffer (NEB, M0530), 200 µM dNTP mix, 500 nM of the respective 
forward and reverse primers and up to 250 ng template DNA. The final volume was adjusted 
to 20 µl with nuclease-free water. For GC-rich template DNA sequences, 3 % DMSO was added 
to the reaction. All reaction components were gently mixed and assembled on ice. The PCR 
3. Materials and Methods 
 
32  
reactions were quickly transferred into a T1 PCR cycler (Biometra, Göttingen). Thermocycling 
conditions are listed in table 3.1. 
 
Table 3.1: Thermocycling conditions with different polymerases. The thermocycling 
conditions for PCRs using OneTaq or Phusion polymerases are shown. Annealing temperatures 
for used primers are described in chapter 3.1.4. The lower annealing temperature was chosen 
for primer pairs with different annealing temperatures. Extension times were adapted to the 
fragment size of the expected PCR product. 
 
 OneTaq polymerase Phusion polymerase  
Step T [°C] Time [s] T [°C] Time [s] Cycles 
Initial denaturation 96 120 98 120 1 
Denaturation 96 30 98 20  
  25-35 Annealing 50-68 30 50-72 30 
Extension 68 60/kb 72 30/kb 
Final extension 68 300 72 300 1 
Hold 4 ∞ 4 ∞ 1 
 
Agarose Gel Electrophoresis 
For analysis of PCR products or DNA digestions, DNA fragments were subjected to agarose 
gel electrophoresis (AGE). Agarose gels were casted with TBE buffer and ethidium bromide at 
a final concentration of 0.5 µg/ml. DNA samples were pre-mixed with DNA gel loading dye 
(Thermo Fisher Scientific, R0611) and loaded onto 0.7 % agarose gels for DNA fragments of 
0.8 – 10 kb or 1.2 % agarose gels for DNA fragments of 0.4 – 5 kb. DNA fragments were 
separated in TBE buffer at 120 V for 45 min and subsequently visualized under an UV 
transilluminator at 265 nm wavelength. Pre-stained DNA ladders with DNA fragments of a 
defined size were separated in parallel to estimate the DNA fragment sizes in the samples 
(Thermo Fisher Scientific, SM0321 or SM0311). 
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Cloning of DNA Fragments 
DNA sequences were modified and assembled in cloning vectors. Therefore, DNA was cleaved 
with suitable restriction enzymes (chapter 3.1.6) and vector backbones were dephosphorylated 
using the Rapid DNA Dephos and Ligation kit (Sigma Aldrich, 04 898 117 001). DNA 
fragments were separated by agarose gel electrophoresis and DNA fragments of interest were 
excised from the agarose gel by using a clean scalpel. The DNA from excised gel fragments 
was extracted using the Qiaquick Gel Extraction kit (Qiagen, 28704). DNA fragments 
generated by PCR were purified using the Qiaquick PCR purifcation kit (Qiagen, 28104). The 
dephosphorylated vector backbones and inserts were ligated at a molecular ratio of 1:3 using 
the Rapid DNA Dephos and Ligation kit. Chemically competent Escherichia coli were 
transformed with 2 µl ligation reaction as described further. 
 
DNA Plasmid Preparations 
DNA plasmids were propagated using bacteria. Therefore, chemically competent Escherichia 
coli (E. coli) were thawed on ice and 2 µl ligation reaction or 1 ng DNA was added. NEB 10-β 
E. coli were used for large DNA plasmids encoding the MV antigenome (NEB, C3019H) and 
One Shot TOP10 E. coli were used for smaller DNA plasmids of up to 8 kb (Thermo Fisher 
Scientific, C404006). After 30 min on ice, bacteria were transformed by heat shock for exactly 
40 s at 42 °C and immediately placed back on ice. After 5 min on ice, 450 µl SOC medium was 
added and bacteria were incubated at 37 °C for 1 h. Subsequently, 40 – 200 µl of the bacterial 
culture were plated onto agar plates (10 cm dishes) containing 100 µg/ml ampicillin. Plates 
were incubated at 37 °C overnight. Single colonies were picked with a sterile toothpick. 
Aliquots of 12.5 µl sterile water were inoculated with the picked colonies and single colony 
PCRs were performed to identify colonies harboring the correct ligation product. In addition, 
aliquots of 4 ml LB medium with 100 µg/ml ampicillin were inoculated with the picked colonies 
and incubated at 37 °C and 800 rpm overnight (mini cultures). On the next day, DNA plasmids 
from the mini cultures were isolated and purified using the QIAprep Spin Miniprep kit (Qiagen, 
27106). For maxi cultures, 200 ml LB medium with 100 µg/ml ampicillin in baffled Erlenmayer 
flasks were inoculated with 100 µl mini culture and incubated at 37 °C and 125 rpm. After 12 
h at 37 °C, DNA plasmids from the maxi cultures were isolated and purified using the QIAfilter 
Plasmid Purification kit (Qiagen, 12263). The obtained DNA concentrations were determined 
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using a Nano-Drop ND-1000 spectrophotometer (Thermo Fisher Scientific) by measuring 
absorbance at 260 nm wavelength. The correct DNA sequences were validated by cleavage of 
the DNA plasmids using the restriction enzyme HindIII (chapter 3.1.6) and Sanger sequencing 
(GATC Biotech, Konstanz). 
 
RNA Isolation and cDNA Synthesis 
RNA molecules were isolated from cells to validate transgene expression using the RNeasy 
Mini kit (Qiagen, 74104). Contaminating DNA in the RNA solution was removed by treatment 
with DNase according to the manufacturer’s instructions. The obtained RNA was reverse 
transcribed into complementary DNA (cDNA) using the Maxima H Minus First Strand cDNA 
Synthesis kit (Thermo Fisher Scientific, K1681). Primers specific for the gene of interest were 
used to amplify the respective DNA fragments from the cDNA by PCR. PCR products were 
analyzed by agarose gel electrophoresis as described above. 
 
3.2.2. Cell Culture Methods 
Cultivation of Cell Lines 
Cells lines were cultivated in cell culture-treated Nunc EasYFlasks with filter caps (Thermo 
Fisher Scientific, 156499 (75 cm2), 159910 (175 cm2)). For subcultivation, cells at 
approximately 80 % confluency were washed with D-PBS and dissociated using 0.05 % trypsin-
EDTA (Thermo Fisher Scientific, 25300054). After cells have dissociated, complete growth 
medium (chapter 3.1.8) was added and cells were subcultivated at a ratio of 1:20. All cell lines 
were maintained at 37 °C in a humidified atmosphere with 5 % CO2. For seeding, dissociated 
cells were stained with 0.4 % trypan blue solution (Sigma-Aldrich, T8154) and counted using 
a Neubauer-improved hemocytometer (Marienfeld, 0640010). All cell lines were routinely 
tested for Mycoplasma contamination using the PCR-based VenorGeM Mycoplasma Detection 
kit (Sigma-Aldrich, MP0025). Cell culture medium was supplemented with fetal calf serum 
(FCS) (Biosera). Beforehand, FCS was heat-inactivated at 56 °C for 30 min and filtrated 
through a 0.22 µm pore-size EMD Millipore Stericup Sterile Vacuum Filter Unit (Thermo 
Fisher Scientific, SCGPU05RE). 
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Cryopreservation of Cell Lines 
Cell lines were cryopreserved for long-term storage in liquid nitrogen. Therefore, cells were 
washed with D-PBS and cell numbers were determined as describes above. Cell pellets were 
gently resuspended in freezing medium (culture medium supplemented with 60 % (v/v) FCS 
and 10 % (v/v) DMSO) at a concentration of 1x106 cells/ml. One ml aliquots were gently 
transferred into cryogenic tubes (Thermo Fisher Scientific, 375418). Tubes were placed into 
precooled (at +4 °C) freezing containers (Thermo Fisher Scientific, 5100-0001) and 
immediately stored at -80 °C. After 24 hours, cells were stored in liquid nitrogen tanks for long-
term storage. 
 
Cultivation of Primary Human Colorectal Cancer Spheroids 
Tumor spheroid cultures (TSCs) were derived from primary human colorectal cancer tissues or 
colorectal cancer derived metastases. Tumor fragments were obtained from the University 
Hospital Heidelberg in accordance with the Declaration of Helsinki. Informed consent was 
given by each patient as approved by the Heidelberg University Ethics Review Board. Single-
cell suspensions from tumor fragments were prepared by mechanical dissociation and treatment 
with Dispase (BD Biosciences, 354235). Single-cell suspensions were cultured under non-
adhesive conditions in serum-free medium supplemented with growth factors (chapter 3.1.8). 
After a few days, cultured cells formed multicellular spheroids. Primary TSCs were tested for 
authenticity and contamination by Multiplex Cell Line Authentication (MCA) and Cell 
Contamination Test Analyses (McCT) (Multiplexion, Heidelberg). 
 
Isolation of Human PBMCs 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples obtained from 
healthy donors. Informed consent was given by each donor as approved by the Heidelberg 
University Ethics Review Board. For isolation of PBMCs, sterile Leucosep tubes (Greiner Bio 
One, 227 290) were filled with 15 ml separation medium (Ficoll Paque Plus, GE Healthcare, 
17-1440-02). Whole blood samples were diluted 2 to 3-fold in D-PBS supplemented with 2 
mM EDTA. Diluted blood samples were poured into the prepared Leucosep tubes (35 ml per 
tube). Tubes were centrifuged at 400 x g, room temperature for 30 min without brakes. The 
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PBMC-containing layers were extracted and pooled. PBMCs were washed with D-PBS 
supplemented with 2 mM EDTA and centrifuged once at 300 x g, room temperature for 10 min 
and subsequently twice at 200 x g, room temperature for 10 min. Cell numbers were determined 
as described above. 
 
Isolation of Splenocytes 
Spleens were explanted from C57BL/6J mice and stored on ice in D-PBS until further 
processing. Within 2 hours, spleens were meshed through 100 µm cell strainers (Neolab, 
352360) into 10 ml D-PBS. Splenocytes were centrifuged at 300 x g for 5 min and pellets were 
resuspended in 1 ml ACK lysing buffer (Thermo Fisher Scientific, A1049201). After 10 min 
incubation at room temperature, ACK lysing solution was diluted with 9 ml D-PBS and cells 
were centrifuged at 300 x g for 5 min, resuspended in 1 ml D-PBS, counted and stored on ice 
until further use. 
 
Isolation of Murine T cells from Splenocytes 
Murine T cells were isolated from splenocytes using the Pan T Cell Isolation kit II (Miltenyi 
Biotec, 130-095-130) according to the manufacturer’s instruction. In brief, T cells were isolated 
from splenocytes by negative selection using magnetically activated cell sorting (MACS). Non-
T cells were labeled with biotinylated antibodies and anti-biotin magnetic beads. Splenocytes 
were loaded onto MS columns (Miltenyi Biotec, 130-042-201) and the columns were placed 
into a magnetic stand. Labeled non-T cells were retained and unlabeled T cells were washed 
out. T cells were collected, counted and stored on ice until further use. 
3.2.3. Recombinant Measles Viruses 
Rescue of Viral Particles 
Recombinant measles virus particles were rescued from DNA plasmids using the RNA 
polymerase II-dependent expression system described by Martin et al. (156). In brief, 5 µg 
DNA plasmids encoding the MV antigenome, 500 ng pCG N, 100 ng pCG P, 500 ng pCG L 
and 100 ng pcDI dsRed were mixed with the transfection reagent FuGENE HD (Promega, 
E2311). The DNA and the transfection reagent were mixed in 200 µl DMEM without 
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supplements at a final concentration of 3 µl FuGENE HD per µg DNA. Vero cells in 6-well 
plates at 70 % confluency were washed twice and 1.8 ml DMEM supplemented with 2 % FCS 
and 50 µg/ml kanamycin was added. The transfection mixture was added dropwise and cells 
were incubated at 37 °C and 5 % CO2. Twenty-four hours post transfection, the transfection 
medium was replaced by DMEM supplemented with 10 % FCS and 50 µg/ml kanamycin. The 
formation of syncytia was monitored daily. When syncytia had formed, medium was removed 
and cells were scraped in 1 ml OptiMEM using a cell lifter (Sigma-Aldrich, CLS3008). Scraped 
cell suspensions were vortexed briefly and used to propagate the rescued virus. 
 
Measles Virus Propagation 
For the first propagation after the rescue of viral particles, Vero cells were seeded in a 10 cm 
dish. At 90 % confluency, culture medium was replaced by 4 ml OptiMEM and cells were 
inoculated with 0.5 ml of the cell suspension from the rescue of viral particles. Cells were 
incubated at 32 °C in a humidified atmosphere with 5 % CO2. Twelve hours after the 
inoculation, 6 ml DMEM supplemented with 10 % FCS was added to each 10 cm dish. Cells 
were incubated at 32 °C until syncytia have spread throughout the entire dish (approximately 
55 to 65 h after inoculation). Then, medium was replaced by 1 ml OptiMEM and cells were 
scraped. The resulting cell suspension was briefly vortexed, frozen in liquid nitrogen and stored 
at -80 °C. Frozen cell suspensions were thawed at 37 °C, briefly vortexed and centrifuged for 
5 min at 5,000 x g and 4 °C. The supernatant was split in 100 µl (for titration assay) and 900 µl 
(for further propagation) and aliquots were frozen in liquid nitrogen and stored at -80 °C. Virus 
titers were determined in titration assays as described further. For further propagations, Vero 
cells were seeded in 15 cm dishes (up to 40 dishes per virus for animal studies). At 90 % 
confluency, culture medium was replaced by 8 ml OptiMEM and cells were inoculated with the 
recombinant measles virus at a multiplicity of infection (MOI) of 0.03. In general, the MOI 
describes the ratio of an agents (here: infectious viral particles) to infection targets (here: Vero 
cells). An MOI of 0.03 means that a certain number of cells X is inoculated with X*0.03 
infectious viral particles. Inoculated cells were incubated at 32 °C in a humidified atmosphere 
with 5 % CO2. Twelve hours after the inoculation, 8 ml DMEM supplemented with 10 % FCS 
was added to each 15 cm dish. Cells were incubated at 32 °C and viral particles were harvested 
as described above. 
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Titration Assay 
The concentration of cell infectious particles in virus suspensions was determined by titration 
assays. Therefore, virus suspensions were titrated in 10-fold dilution steps in DMEM 
supplemented with 10 % FCS on 96-well plates. Titrations were performed in octuplicates to 
determine titers after virus propagations or quadruplicates for one-step growth curves. Vero 
cells were added at a concentration of 1.5x105 cells/ml and plates were incubated at 37 °C in a 
humidified atmosphere with 5 % CO2. After 48 h, syncytia were counted and virus titers in cell 
infectious units per ml (ciu/ml) were calculated as following: mean number of syncytia per well 
x dilution factor.  
 
Infection Assays to Monitor Cytopathic Effects 
Susceptibility of target cells to MV infection was monitored in infection assays in terms of 
syncytia formation and eGFP expression. Therefore, infection target cell were inoculated with 
the respective MV at an MOI of 0.03 (Vero cells) or at an MOI of 1 (Vero cells, murine target 
cells, TSCs). Cells were monitored for syncytia formation and eGFP expression using a 
Axiovert 200 fluorescence microscope (Carl Zeiss) and Axiovision 4.7 software (Carl Zeiss). 
Representative images were acquired 24 to 48 h post infection at a 50-fold magnification. 
 
Virus Growth Kinetics 
Virus growth kinetics on different target cells were assessed by generating one-step growth 
curves. Cells were seeded at 80 % confluency in 12-well plates (1x105 Vero cells and murine 
cells per well, respectively) or 24-well plates (5x104 TSC cells per well). Cells were inoculated 
in duplicates per time point with the respective MV at an MOI of 1 in 300 µl OptiMEM and 
150 µl OptiMEM, respectively. Plates were incubated at 37 °C in a humidified atmosphere with 
5 % CO2. After 12 hours, the inoculum was replaced by 1 ml culture medium (RPMI 
supplemented with 10 % FCS for TSCs). Cells were scraped and harvested in the culture 
medium at 12, 24, 36, 48, 72, and 96 hours post infection. Progeny viral particles were 
determined in titration assays as described above to generate growth curves. 
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Cell Viability Assay 
Viability of cells after inoculation with MV was analyzed to assess virus-mediated cytotoxicity 
using the Colorimetric Cell Viability kit III (PromoCell, PK-CA20-300-1000) according to the 
manufacturer’s instruction. In brief, cells were seeded at 80 % confluency in 12-well plates 
(1x105 cells per well). Cells were inoculated in triplicates per time point with the respective 
MV at an MOI of 1 in 300 µl OptiMEM. Plates were incubated at 37 °C in a humidified 
atmosphere with 5 % CO2. After 12 hours, the inoculum was replaced by 1 ml culture medium 
and cell viability was determined at 12, 24, 36, 48, 72, and 96 hours post infection. Thereby, 
the metabolic activity of mitochondrial enzymes in living cells was determined. The tetrazolium 
salt XTT (2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) is 
reduced into a colored formazan compound, which was measured using a spectrophotometer 
(Tecan Infinite M200) at a wavelength of 450 nm. Background absorbance at a wavelength of 
630 nm was subtracted from signal absorbance. Percentage of viable cells was calculated in 
relation to metabolic activity of mock-infected cells. 
 
BiTE Production 
Vero cells were seeded at 95 % confluency in 15 cm dishes (1.2x107 cells per dish) and allowed 
to adhere for 5 h. Subsequently, culture medium was removed and cells were inoculated with 
the respective MV at an MOI of 0.03 in 10 ml serum-free OptiPRO SFM. Dishes were incubated 
at 37 °C in a humidified atmosphere with 5 % CO2. After 12 h, the inoculum was replaced by 
12 ml fresh OptiPRO SFM and dishes were transferred to 32 °C. Supernatants were harvested 
when syncytia had spread throughout the entire dish (approximately 60 to 65 h after 
inoculation). Subsequently, supernatants were centrifuged at 4,000 x g for 10 min at 4 °C and 
passed through a 0.22 µm pore-size syringe filter unit (Merck, SLGP033RB). BiTEs were 
purified from the filtered supernatants as described below. 
 
BiTE Purification 
BiTEs were purified by affinity chromatography using Ni-NTA spin columns (Qiagen, 31014) 
according to the manufacturer’s instruction. In brief, 600 µl sterile-filtered supernatant was applied 
to the spin columns and centrifuged at 200 x g for 5 min at 4 °C. This step was repeated up to 10 
times per column (6 ml per column). Then, columns were washed once with 10 mM imidazole 
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solution and twice with 20 mM imidazole solution. BiTEs were eluted from the columns with 500 
mM imidazole solution. Each imidazole solution was prepared with PBS, supplemented with 200 
mM NaCl and set to pH 7.0 to 8.0 with HCl. Eluted BiTEs were washed with PBS and concentrated 
using 15 ml centrifugal filter units with a vertical membrane that retains proteins larger than 10 kDa 
(Merck, UFC901024). Filter units were centrifuged at 4,000 x g for 20 min at 4 °C. The retained 
BiTE-containing fraction was diluted with 15 ml PBS and concentrated twice to reduce imidazole 
concentrations below 0.1 mM. BiTE concentrations were measured using Novagen BCA Protein 
Assay kit (Merck, 712853) according to the manufacturer’s instructions. 
 
3.2.4. Measles Virus Encoded Transgene Expression 
SDS-PAGE 
BiTE expression by MV-infected cells was analyzed by Western blot, Coomassie Blue staining 
and magnetic pull-down of labeled cells. Therefore, proteins were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Cell lysates were prepared using 
RIPA buffer (Thermo Fisher Scientific, 89900). To investigate BiTE secretion into the cell 
culture medium by MV-infected cells, supernatants were concentrated 20-fold using 15 ml 
centrifugal filter units (Merck, UFC901024) or BiTEs were purified beforehand. Samples were 
supplemented with Laemmli buffer (Bio-Rad, 61-0747) and incubated at 95 °C for 5 min. 
Subsequently, samples were cooled on ice and briefly spun down. Samples were loaded onto a 12 
% polyacrylamide gel (Bio-Rad, 4561041) in running buffer (Carl-Roth, 3060.1). A prestained 
protein ladder (Thermo Fisher Scientific, 26616) served as molecular weight standard. Proteins 
were separated at 200 V for 40 min at room temperature. 
 
Western Blot 
After SDS-PAGE, separated proteins were transferred onto a methanol activated 
polyvinylidene fluoride (PVDF) membrane (Merck, IPVH07850). The protein transfer was 
performed in a wet-chamber with Tris-Glycine transfer buffer (Thermo Fisher Scientific, 
LC3675) at 100 V and 4 °C for 1 h. Subsequently, membranes were blocked in 5 % powdered 
milk (Carl-Roth, T145.2) in TBS-T (Carl-Roth, 1061.1) at 4 °C overnight. BiTEs were detected 
using mouse anti-HA antibody (clone HA-7, diluted 1:10,000 in 5 % powdered milk in TBS-
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T) for 1 h at room temperature. Blots were washed three times for 10 min with TBS-T to remove 
unbound anti-HA antibody. BiTE-bound anti-HA antibody was detected using HRP-coupled 
rabbit anti-mouse IgG antibody (diluted 1:2,000 in 5 % powdered milk in TBS-T) for 1 h at 
room temperature. Blots were washed three times for 10 min with TBS-T. Blots were covered 
with 1 ml chemiluminescent substrate (Thermo Fisher Scientific, 10177533) and incubated for 
3 min in the dark. HRP-specific signals were recorded using a ChemiDOC XRS Imaging 
System (Bio-Rad). 
 
Coomassie Blue Staining 
After SDS-PAGE, separated proteins were stained with Imperial Protein Stain (Thermo Fisher 
Scientific, 24615) according to manufacturer’s instruction. In brief, gels were washed three 
times for 5 min with water. Subsequently, gels were covered with 25 ml of the staining reagent 
and incubated on a shaker. After 2 h, the staining reagent was removed and gels were washed 
with 200 ml water overnight. Images of the stained gels were acquired using a ChemiDOC XRS 
Imaging System (Bio-Rad). 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
BiTE expression, BiTE binding and BiTE plasma levels were analyzed by ELISA. Therefore, 
ninety-six-well plates (Thermo Fisher Scientific, 44-2404-21) were coated with recombinant 
human CEA (5 µg/ml, Bio-Rad, PHP282), human CD20 (1 µg/ml, Abnova, H00000931-P01), 
human CD3 (5 µg/ml, biorbyt, orb138433), mouse CD3 (5 µg/ml, biorbyt, orb138426), mouse 
PD-L1 (5 µg/ml, Thermo Fisher Scientific, 50010M08H25) or mouse CTLA-4 (5 µg/ml, 
Thermo Fisher Scientific, 50503M08H25) in 100 µl PBS per well. After incubation at 4 °C 
overnight, wells were blocked with blocking buffer (D-PBS supplemented with 5 % FCS) for 
2 h at room temperature. Blocked wells were washed three times with 200 µl D-PBS. Samples 
were prepared in 100 µl D-PBS, added to the plate and incubated for 2 h at room temperature. 
Subsequently, plates were washed three times with 200 µl washing buffer (D-PBS 
supplemented with 0.05% Tween20 (Biotium, 22002)). Next, plates were incubated with 100 
µl anti-HA-biotin antibody per well (1:500 in blocking buffer, clone 3F10, Sigma-Aldrich, 
12158167001). After 1 h at room temperature, plates were washed five times with 200 µl 
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washing buffer. Subsequently, plates were incubated with 100 µl horseradish peroxidase-
streptavidin per well (1 mg/ml, Dianova, 016-030-084) for 15 min at room temperature. 
Afterwards, plates were washed seven times with 200 µl washing buffer and BiTEs were 
detected with 100 µl 1-Step Ultra TMB-ELISA substrate solution per well (Thermo Fisher 
Scientific, 34028). After 5-30 min, the enzymatic reaction was stopped by adding 100 µl Stop 
Solution (Takara, MK021). Absorbance was measured using a spectrophotometer (Tecan 
Infinite M200) at a wavelength of 450 nm. Background absorbance at a wavelength of 570 nm 
was subtracted from signal absorbance. 
 
Magnetic Pull-Down of BiTE-Labeled Cells 
An assay with the magnetic pull-down of BiTE-labeled cells was established to validate BiTE 
binding to target cells. Therefore, 2.5x106 target cells were incubated in 200 µl D-PBS with 2 
µg/ml BiTE for 30 min on ice. Cells were washed with D-PBS and resuspended in 200 µl D-
PBS with anti-HA-biotin antibody (1:50, clone 3F10, Sigma-Aldrich, 12158167001). After 30 
min on ice, cells were washed twice with D-PBS. Cells were resuspended in 80 µl D-PBS and 
20 µl anti-biotin magnetic beads were added (Miltenyi Biotec, 130-090-485). After 15 min on 
ice, cells were washed with MACS buffer (D-PBS supplemented with 1 % FCS and 2 mM 
EDTA). Cells were applied to MS columns (Miltenyi Biotec, 130-042-201) and columns were 
placed into a magnetic stand. Columns were washed three times with 500 µl MACS buffer and 
flow through fractions were collected. Magnetically labeled (BiTE-bound cells) were retained 
in the columns and unlabeled cells were washed out. Columns were removed from the magnetic 
stand. One ml MACS buffer was applied to the columns and labeled cells were flushed out by 
using the plunger supplied with the columns. Cells from the elution and flow through fractions 
were centrifuged at 300 x g for 5 min at 4 °C. Cell pellets were lysed in 75 µl RIPA buffer. 
Lysis solutions were centrifuged at 16,000 x g for 20 min at 4 °C. Proteins in two µl supernatant 
were separated by SDS-PAGE as described above. Presence of cells in the elution and flow 
through fraction was investigated by Western blot analysis using anti-β-actin-Peroxidase 
(1:20,000, Sigma-Aldrich, A3854). 
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3.2.5. Flow Cytometry 
BiTE binding and antigen expression levels were analyzed by flow cytometry. For analysis of 
BiTE binding, 1x106 target cells were washed with D-PBS and incubated with 1 µg/ml BiTE 
in 100 µl FACS buffer (D-PBS supplemented with 1 % FCS). After 30 min on ice, cells were 
washed with FACS buffer. For analysis of BiTE binding and antigen expression levels, 1x106 
target cells were stained in 50 µl FACS buffer with specific antibodies and isotype controls 
according to the descriptions listed in chapter 3.1.7. Each experiment was designed to include 
unstained and single-color stained samples. For multicolor analysis, fluorescence minus one 
(FMO) controls were included as well. Cells were stained for 30 min in the dark and on ice. If 
mouse cells were analyzed, 1 µl α-mouse CD16/CD32 (Fc block) was added to each sample 5 
min before cells were stained with the specific antibodies. After the staining, cells were washed 
with 1 ml FACS buffer. Cell pellets were resuspended in 500 µl FACS buffer or 500 µl DAPI 
solution (1 µg/ml DAPI in FACS buffer) to discriminate live from dead cells. Subsequently, 
cells were washed with 1 ml FACS buffer. Samples were analyzed using an LSRII flow 
cytometer (BD Biosciences) with FACS Diva software version 8.0.1 (BD Biosciences). For 
each sample, 10,000 events were recorded and analyzed using FlowJo V10 software (Tree Star 
Inc.). 
 
3.2.6. Cytotoxicity Assay 
BiTE-mediated T cell cytotoxicity was evaluated in lactate dehydrogenase (LDH) release 
assays by using the CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega, G1780). 
Tumor cells were co-cultured with murine T cells or human PBMCs. BiTEs were added and 
percentage of specific tumor cell lysis was determined after 24 to 48 hours incubation at 37 °C 
in a humidified atmosphere with 5 % CO2. The optimal tumor cell number depends on the 
intracellular LDH content and was determined for each cell line beforehand. Therefore, 2x104 
tumor cells were titrated in 2-fold dilution steps in 100 µl PBMC medium (RPMI 1640 
supplemented with 10 % FCS, 10 mM HEPES and 1 % ABAM) on 96-well plates (Sigma-
Aldrich, Z707899-162EA). A medium only control was included to assess the unspecific LDH 
content in the medium. Cells were lysed and the amount of released LDH was measured 
according to the manufacturer’s instruction. In brief, 10 µl lysis solution was added to each well 
and the plates were incubated for 45 min at 37 °C. Plates were centrifuged at 250 x g for 4 min 
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at room temperature. Fifty µl of each supernatant was transferred to new 96-well plates. Fifty 
µl substrate was added per well and incubated in the dark for 30 min at room temperature. 
Subsequently, 50 µl stop solution was added per well and signal absorbance was measured at a 
wavelength of 490 nm using a spectrophotometer (Tecan Infinite M200). For the optimal tumor 
cell number, the signal absorbance values were at least 2-fold higher compared to the 
background absorbance in the medium only controls. 
For the cytotoxicity assays, murine T cells were isolated from splenocytes as described above. 
5x103 MC38-CEA cells were incubated for 48 hours with murine T cells at a ratio of 12:1 and 
1 µg/ml mCD3xCEA BiTE was titrated in 10-fold dilution steps. Murine cytotoxic T 
lymphocytes (mCTLs) were incubated for 24 hours with 5x103 MC38-CEA cells and 1 µg/ml 
mCD3xCEA BiTE. mCTLs were titrated in 2-fold dilution steps starting with a ratio of 25:1. 
Human PBMCs were isolated from healthy donor blood as described above. 5x103 MC38-CEA 
cells were incubated for 24 hours with PBMCs at a ratio of 50:1. Ten µg/ml hCD3xCEA BiTE 
was titrated in 10-fold dilution steps. 2.5x103 TSC8, 5x103 TSC17 or 1x104 TSC23 were 
incubated for 24 hours with PBMCs at a ratio of 50:1. One µg/ml hCD3xCEA BiTE was titrated 
in 10-fold dilution steps. Each experiment was designed to include medium only control and 
spontaneous and maximum LDH release of tumor and immune cells, respectively. Cytotoxicity 
assays were developed as described above. Background absorbance was subtracted from each 
signal absorbance value. Percentage specific lysis of tumor cells was calculated as following: 
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3.2.7. Cytometric Bead Array (CBA) 
Cytometric bead arrays (CBA) were performed to analyze BiTE-mediated cytokine secretion 
by T cells. Mouse and human Th1/Th2/Th17 Cytokine kits were used according to the 
manufacturers’s instruction, respectively (BD Biosciences, 560485/560484). In brief, murine T 
cells isolated from splenocytes or human donor-derived PBMCs were co-cultured with 5x103 
tumor cells at a ratio of 50:1 in 200 µl PBMC medium (RPMI 1640 supplemented with 10 % 
FCS, 10 mM HEPES and 1 % ABAM). BiTEs were added to a final concentration of 1 µg/ml. 
After 24 h at 37 °C in a humidified atmosphere with 5 % CO2, cells were centrifuged at 2,000 
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x g for 10 min at 4 °C and supernatants were transferred to new reaction tubes, twice. 
Supernatants were stored at -80 °C until analysis. Samples with non-target tumor cells or BiTEs 
targeting non-relevant tumor antigens were used as internal controls. 
 
3.2.8. In Vivo Experiments 
All experimental procedures, which involved the use of animals, were approved by the 
responsible Animal Protection Officer at the German Cancer Research Center (DKFZ, 
Heidelberg) and by the regional authority according to the German Animal Protection Law. 
C57BL/6J mice were obtained from Harlan Laboratories (Rossdorf) or the Central Animal 
Laboratory of the DKFZ. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from 
Charles River (Sulzbach). Animals were housed in pathogen-free, individually ventilated cages 
(IVCs) at the Animal Laboratory Services Core Facility at the DKFZ. Six to eight weeks old, 
female mice were used for all experiments. 
 
Tumor Cell Implantation 
Low-passage tumor cells were expanded under cell type-specific conditions as described above. 
At the day of implantation, cells were dissociated and washed twice with D-PBS. Cell numbers 
were determined as described above and cells were resuspended at a final concentration of 
1x107 cells/ml in D-PBS. TSCs were resuspended in 100 µl matrigel (BD Biosciences, 354248). 
Cells were stored on ice and implanted within 2 hours. 1x106 tumor cells (100 µl) were injected 
subcutaneously into the shaved, right flank region of each mouse using 1 ml syringes (VWR, 
720-2561) and 26 G needles (B. Braun, 1023-0100). 
 
Monitoring and Treatment 
After tumor cell implantation, mice were monitored daily. When developing tumors were 
visible, tumors were measured daily using a digital caliper. Tumor volumes were estimated by 
using following formula:					 	0.5. Treatment was 
initiated when tumors reached a mean volume of 50 mm3 (for murine tumor cells) and 100 mm3 
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(for TSCs), respectively. MC38-CEA-bearing mice were treated with intratumoral injections of 
100 µl of 1x106 ciu of MV-BiTE or carrier fluid (OptiMEM) on four consecutive days. B16-
CD20-CD46-bearing mice received the same treatment for five consecutive days. TSC-bearing 
mice were treated with intratumoral injections of 50 µl of 1x106 ciu of MV-BiTE or carrier 
fluid (OptiMEM) on four consecutive days. On the first day of treatment, TSC-bearing mice 
additionally received 50 µl of 1x107 healthy donor-derived PBMCs or carrier fluid (PBS) 
intratumorally. For all intratumoral injections, 1 ml syringes and 26 G needles were used. 
Tumors were measured every third day. Endpoints were defined as tumor volumes of >1,000 
mm3, tumor diameter > 15 mm, tumor ulceration, tumor bleeding or severe signs of illness. 
Severe signs of illness include one or more of the following symptoms: ruffled fur, squinted 
eyes, inactivity or non-responsiveness, hunched posture, labored breathing or body weight loss 
>20 %. Mice fulfilling one or more of the predefined endpoints were sacrificed. 
 
3.2.9. Analysis of Primary Mouse Material 
Analysis of Tumor-Infiltrating Lymphocytes (TILs) 
TILs were analyzed by flow cytometry. Therefore, explanted tumors were cut into small pieces 
using a clean scalpel. Tumor pieces were incubated in 5 ml digestion buffer (RPMI 1640 
supplemented with 5 % FCS and 200 U/ml collagenase type I (Thermo Fisher Scientific, 
17100017)) for 30 min at 37 °C. Digested tumor cells were meshed through a 100 µm cell 
strainer (Neolab, 352360) into 10 ml D-PBS. Cell numbers were determined as described above 
and centrifuged at 300 x g for 5 min at 4 °C. Cell pellets were resuspended at a final 
concentration of 2x106 cells per 50 µl in FACS buffer (D-PBS supplemented with 1 % FCS). 
Cells were stained with specific antibodies and analyzed as described above. 
 
Analysis of Intratumoral Cytokines 
Intratumoral concentrations of specific cytokines were analyzed using the Cytometric Bead 
Array (CBA) mouse Th1/Th2/Th17 Cytokine kit (BD Biosciences, 560485) according to the 
manufacturer’s instruction. Explanted tumor pieces were frozen in liquid nitrogen and stored at 
-80 °C until further processing. Frozen tumor pieces were thawed on ice and cut into small 
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pieces using a clean scalpel. Tumor pieces were homogenized in lysis buffer (one protease 
inhibitor cocktail Tablet (Sigma-Aldrich, 05892791001) dissolved in 10 mM Tris-HCl (pH 
8.0), 150 mM NaCl, 10 % Glycerol, 5 mM EDTA and 1 % NP-40) using a pestle. Homogenized 
tumor samples were incubated for 1 h at 4 °C under constant rotation. Subsequently, samples 
were sonicated in automated 30 seconds on/off cycles for 7 min at high intensity using a 
sonication system with a cooling water pump (Bioruptor Standard, Diagenode, UCD-200). Cell 
debris was removed by centrifugation at 13,000 x g for 15 min at 4 °C. Supernatants were stored 
at -80 °C until analysis. 
 
Analysis of BiTE Plasma Levels 
Systemic exposure of BiTEs after MV-BiTE treatment was analyzed by ELISA as described 
above (chapter 3.2.4). Peripheral blood was collected from the saphenous vein. Therefore, mice 
were placed in a restraining tube and the left shank and thigh were shaved. The saphenous vein 
was punctured with a 26 G needle and 100 µl blood was collected using a heparin collection 
tube with capillary action (Sarstedt, 16.443). Bleeding was stopped by applying pressure on the 
punctured area using a sterile cotton swab. Plasma was prepared from blood by centrifugation 
for 10 min at 2,000 x g at room temperature and stored at -80 °C until analysis. 
 
3.2.10. Statistical Analysis 
Statistical analyses were performed using GraphPad Prism software (v6.04, GraphPad 
Software). Data show mean with standard deviation (SD). Statistical analyses of column data 
with one independent variable were performed by one-way ANOVA and p values were adjusted 
for multiple comparisons by Tukey’s test. For competitive ELISAs, the mean of each column 
was compared to the mean of one control column and p values were adjusted for multiple 
comparisons by Dunnett’s test. Statistical analyses of grouped data with two independent 
variables were performed by two-way ANOVA and p values were adjusted for multiple 
comparisons by Sidak’s test. Curve comparison of two groups for survival analyses were 
performed by log-rank (Mantle-Cox) test and p values were adjusted for multiple comparison 
by Bonferroni’s correction. 
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4. Results 
The study concept is based on the hypothesis that tumor-targeted expression of bispecific T cell 
engagers (BiTEs) by oncolytic measles viruses (MVs) increases therapeutic antitumor efficacy 
of measles virotherapy. Furthermore, local BiTE expression increases therapeutic BiTE 
concentrations at the tumor site, as compared to systemic BiTE applications. At the same time, 
potential BiTE-related systemic adverse events (AEs) are alleviated. MVs encoding BiTEs 
(MV-BiTE) were generated and characterized in vitro in terms of virus replication, oncolytic 
activity and transgene expression. BiTEs from MV-BiTE-infected cells were purified and 
analyzed for binding specificity and cytotoxicity in co-culture assays in vitro. Therapeutic 
efficacy of MV-BiTE was assessed in immunocompetent mouse models of colon 
adenocarcinoma and melanoma*, as well as in xenografts with patient-derived colorectal cancer 
spheroids in immunodeficient mice. 
4.1. Generation of BiTE-encoding Measles Viruses 
4.1.1. Cloning of BiTE Antibody Constructs 
BiTE antibodies generally comprise two single chain variable fragments (scFvs), which are 
translated in tandem from a single gene (Figure 4.1). Therefore, the variable chain domains 
were connected by non-immunogenic, flexible peptide linkers. One scFv contains the entire 
complementarity-determining region (CDR) and consists of a variable heavy and light chain 
domain (VH and VL). The VH and VL domains were connected by three repeats of the amino 
acid (AA) sequence glycine-glycine-glycine-glycine-serine ((Gly4Ser)3). The (Gly4Ser)3-
sequence is a standard linker that improves stability of the scFvs. The 15 AAs span a distance 
of approximately 35 Å, which is a sufficient length to ensure monomeric formation of scFvs 
(157). The two scFvs were connected by a short middle linker of five AAs (Gly4Ser) to ensure 
close proximity of the simultaneously engaged T cell and tumor cell. A human influenza 
hemagglutinin (HA)-tag and a hexa histidine (His6)-tag were fused to the N- and C-terminus, 
respectively. The N-terminal Kozak consensus sequence is meant to enhance translation of 
                                                 
*Johannes Heidbüchel joined the BiTE project as a Master student under the supervision of Tobias Speck. He 
continued working with the CD20-targeting MV-BiTEs as a PhD student. All results concerning the B16-CD20-
CD46 melanoma model are shown in the Appendix. His contribution is always indicated. 
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BiTE mRNA transcripts and the immunoglobulin kappa light chain signal sequence (Igκ leader) 
to promote protein secretion after translation. Different BiTE antibody constructs were 
generated to target human CD3 (OKT3) or murine CD3 (145-2C11) and human 
carcinoembryonic antigen (CEA) (MFE-23) or human CD20 (B9E9), respectively (Figure 4.1). 
4.1.2. Cloning of Recombinant MV-BiTE 
Measles viruses (MVs) derived from the Edmonston B vaccine strain (chapter 1.5.2) were 
genetically modified to express secretable BiTEs (MV-BiTE). The utilized Edmonston B 
derivative has additional unique restriction sites by NarI and SpeI elimination (NSe). pcpNSe 
plasmids encode the antigenomic MV-NSe cDNA and can be modified to carry additional 
transcription units (ATUs) that enable transgene expression in infected cells. MV-NSe 
containing an ATU downstream of the H open reading frame (ORF) and enhanced green 
fluorescent protein (eGFP) in leader position (upstream of N ORF) have been generated 
previously (pcpNSe ld-eGFP H-ATU; pcpNSe H-ATU) (92). Each BiTE-encoding sequence 
was inserted into an ATU downstream of the H ORF (Figure 4.1). 
 
Figure 4.1: Schematic representation of the recombinant MV genomes and transgenes. 
(A) The BiTE-encoding transgene T was inserted downstream of the H gene open reading frame 
(ORF). MV-BiTE, which additionally encode the eGFP sequence E upstream of the N gene 
ORF were generated as well. (B) Four different BiTE-encoding transgenes T1 – T4 were 
generated. T1 and T3 encode for human CD3-targeting BiTEs, which are directed against the 
tumor associated antigens human CEA and human CD20, respectively. T2 and T4 encode for 
murine CD3-targeting BiTEs, which are as well directed against human CEA and human CD20, 
respectively. The transgene sequence lengths range from 1,602 to 1,626 base pairs (bp). 
A 
B 
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4.2. Characterization of Recombinant Measles Viruses 
4.2.1. Susceptibility of Target Cells to MV-BiTE Infection 
The capability of eGFP-encoding MV-BiTE to infect target cells was investigated. The 
expression of eGFP and syncytia formation served as indicators for productivity of infection 
and viral spread. 
Vero cells are the MV producer cell line and highly susceptible to MV infection (Figure 4.2 A). 
Images of Vero cells are included in the analysis as an internal positive control. Expectedly, 
strong eGFP signals and the formation of large syncytia were observed after MV-infection of 
Vero cells. 
Furthermore, we inoculated murine cell lines with MV-BiTE, which were used for the in vivo 
efficacy studies. B16 and MC38 are murine melanoma and colon adenocarcinoma cell lines, 
respectively, and are syngeneic and tumorigenic to C57BL/6 mice. Murine cells lack the 
expression of MV entry receptors and are therefore not susceptible to MV infection. 
Expectedly, inoculation of MC38-CEA cells with recombinant MV resulted in low levels of 
eGFP expression and no syncytia formation. MC38-CEA-CD46 cells express human CD46, an 
entry receptor for MV vaccine strains (chapter 1.5.2). However, murine cells are generally less 
permissive for MV infection as compared with human or non-human primate cells. Expectedly, 
inoculation of MC38-CEA-CD46 cells with recombinant MV resulted in moderate levels of 
eGFP expression and the formation of small syncytia (Figure 4.2 B). Similar levels of eGFP 
and syncytia formation were observed for MV-infected B16-CD20-CD46 (Figure A.1).* 
Tumor spheroid cultures (TSCs) from patients with colon cancer were used to study therapeutic 
efficacy of MV-BiTE in xenografts. Three different TSCs with varying levels of endogenous 
CEA expression were inoculated with MV-BiTE (Figure 4.10 D). Strong eGFP expression and 
the formation of large syncytia were observed (Figure 4.2 C). 
                                                 
*
 Results generated by Tobias Speck 
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Figure 4.2: Susceptibility of target cells to MV-BiTE. (A) Vero cells were inoculated with 
MV-eGFP-mCD3xCEA at a multiplicity of infection (MOI) of 0.03.  Images were acquired 48 
h post inoculation. (B) The susceptibility for MV infection of MC38-CEA and MC38-CEA-
CD46 was compared to Vero cells. Cells were inoculated with MV-eGFP-mCD3xCEA at an 
MOI of 1. Images were acquired 48 h post inoculation. (C) Low-passage tumor spheroid 
cultures TSC8, TSC17 and TSC23 were inoculated with MV-eGFP-hCD3xCEA at an MOI of 
1. Images were acquired 24 h post inoculation. (A-C) Scale bars: 200 µm. 
C 
A 
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4.2.2. Growth Kinetics of Recombinant MV-BiTE 
MV-mediated cytopathic effects and transgene expression correlate with the capacity of the 
viruses to replicate. Therefore, we generated one-step growth curves to characterize replication 
kinetics of the recombinant viruses as compared with the unmodified MV. 
Replication kinetics of all non-eGFP-encoding MV-BiTE were assessed on Vero cells, which 
are the relevant constructs for the in vivo efficacy studies. All tested recombinant viruses had 
similar replication kinetics, which were comparable to replication of the unmodified MV 
(Figure 4.3). Production of virus progeny peaked at 36 h post infection with 2.25 – 7.75x105 
cell infectious units (ciu)/ml. Next, MV-BiTE replication kinetics were assessed on murine cell 
lines. Consistent with the infection tests, the least virus progeny were generated on MC38-CEA 
with maximum titers in the range of 4x102 – 5.25x103 ciu/ml 12-24 h post infection. Higher 
virus titers were generated on MC38-CEA-CD46, as compared to MC38-CEA. Maximum titers 
of up to 1.25x104 ciu/ml were reached 36-48 h post infection. Highest virus titers on murine 
cells were reached on B16-CD20-CD46 with 1.75 – 5.75x105 ciu/ml 36-48 h post infection, a 
similar range as compared to virus progeny generated on Vero cells (Figure A.2 A).* However 
in comparison to Vero cells, virus replication was delayed on B16-CD20-CD46 and dropped 
close to or below detection limit (= 25 ciu/ml) at 96 h post infection. Virus replication was 
moderate on TSCs with highest titers in the range of 6x102 – 1.9x103 ciu/ml (TSC8), 6x103 – 
1.1x104 ciu/ml (TSC17) and 1.55x103 - 4.5x103 ciu/ml (TSC23). However, virus replication on 
all TSCs was stable and continued beyond 96 h. Conclusively, replication of the recombinant 
MVs was not compromised by insertion of BiTE-encoding sequences in an ATU downstream 
of the H ORF. 
4.2.3. Direct Cytotoxic Capacity of Recombinant MV-BiTE 
All tested MV-BiTE had similar replication kinetics in one-step growth curves. However, virus 
replication largely differed among the various tumor cells. We performed metabolic cell 
viability assays (XTT) to assess MV-mediated cytopathic effects on the tested tumor cells. 
                                                 
*
 Results generated by Tobias Speck and Johannes Heidbüchel 
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MV-BiTE and unmodified MV similarly reduced cell viability of Vero cells at 48 h post 
infection by 90 % as compared to mock-treated Vero cells (Figure 4.4). Consistent with 
replication kinetics, MV cytopathic effects on murine cells were delayed. Viability of MC38-
CEA-CD46 cells was reduced by 90 % at 96 h post infection. In contrast, MC38-CEA cell 
viability was reduced by 40 – 60 % at most at 96 h post infection. Viability of B16-CD20-CD46 
cells was reduced by 56 – 72 % at 48 h post infection and relative viability increased to 70 – 80 
% at 96 h post infection (Figure A.2 B).* 
Figure 4.3: Replication kinetics of MV-BiTE. Indicated cells were inoculated with MV-BiTE 
and unmodified MV at a multiplicity of infection (MOI) of 1. Viral progeny were determined 
by titration assays 12, 24, 36, 48, 72 and 96 hours post infection. Titration assays were 
performed in quadruplicates, which results in a detection limit of 25 cell infectious units 
(ciu)/ml. One-step growth curves were generated to compare MV replication kinetics in terms 
of viral progeny in ciu/ml. 
                                                 
*
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Figure 4.4: Cytotoxic capacity of MV-BiTE. Indicated cells were inoculated with medium 
only (mock), MV-BiTE or unmodified MV at a multiplicity of infection (MOI) of 1. Cell 
viability was determined in triplicates 12, 24, 36, 48, 72 and 96 hours post infection. Cell 
viability in % was normalized to cell viability of non-infected cells (mock), as described in 
chapter 3.2.3. 
 
4.2.4. Transgene Expression of Recombinant MV-BiTE 
BiTE expression from MV-BiTE-infected cells was analyzed by RT-PCR and Western blot. 
For RT-PCR, Vero cells were infected with the respective MV-BiTE at an MOI of 0.03. BiTE 
mRNA was detected in cell lysates 95 h post infection (Figure 4.5 A). For Western blot analysis, 
Vero (MOI 0.03) or MC38-CEA-CD46 cells (MOI 1) were infected with MV-mCD3xCEA. 
BiTE expression was analyzed in cell lysates by anti-HA antibody staining 12 – 96 h post 
infection (Figure 4.5 B). BiTE expression in Vero cells was first detectable at 36 h post infection 
and continually increased until 96 h post infection. Similarly, in MC38-CEA-CD46 cells, BiTE 
expression was first detectable at 36 h post infection. However, expression peaked at 48 h post 
infection and then gradually decreased until 96 h post infection. 
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Figure 4.5: BiTE expression by MV-BiTE-infected cells. (A) RT-PCR: Vero cells were 
infected with MV-BiTE at a multiplicity of infection (MOI) of 0.03. Cells were lysed at 95 h 
post infection and RNA was isolated. BiTE-specific sequences from the transcribed cDNA were 
amplified by PCR and subjected to gel electrophoresis. Fragments of the expected size of 
approximately 1,500 base pairs (bp) were detected. Minus reverse transcriptase (-RT) samples 
served as negative controls for DNA contaminations in the RNA samples. (B) Western blot 
analysis: Cells were infected at MOI 0.03 (Vero) or MOI 1 (MC38-CEA-CD46). Cells were 
lysed at indicated time points and proteins were separated by SDS-PAGE. Proteins were blotted 
onto PVDF membranes and stained with anti-HA (BiTE) or anti-β-actin antibodies (loading 
control). 
 
BiTE secretion from MV-BiTE-infected cells into culture supernatant was investigated by 
protein staining of SDS-PAGE and ELISA. For SDS-PAGE analysis, cell-free supernatants 
from MV-BiTE-infected Vero cells were harvested and concentrated 20-fold using centrifugal 
filter units. Proteins were separated on an SDS-PAGE gel and subsequently stained with a 
coomassie dye. Proteins with the expected molecular weight of BiTEs of approximately 58 
kilodalton (kDa) were detected in culture supernatants of MV-BiTE-infected cells (Figure 4.6 
A). In the supernatant of non-infected cells, no protein of the corresponding molecular weight 
was detectable. For ELISA, cells were infected with MV-BiTE at cell type-specific MOIs. Cell-
free supernatants were harvested at 24 – 96 h post infection and analyzed by ELISA with 
recombinant human protein. Consistent with Western blot analysis of cell lysates, BiTE 
secretion by MV-BiTE-infected Vero cells was detectable after 24 h post infection and BiTE 
concentration continually increased over time until 96 h post infection (Figure 4.6 B). BiTE 
concentrations in culture supernatants from MV-BiTE-infected MC38-CEA-CD46 cells peaked 
at 48 – 72 h post infection and decreased until 96 h post infection. However, maximum BiTE 
concentrations were three times lower as compared with BiTE concentrations in the supernatant 
of Vero cells. Low levels of BiTE were secreted by MV-BiTE-infected MC38-CEA cells. 
Consistent with replication kinetics, maximum BiTE concentrations were reached at 24 h post 
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infection and declined over time until 96 h post infection. Furthermore, supernatants from MV-
BiTE-infected TSCs were analyzed by ELISA and compared to supernatants from TSCs 
infected with unmodified MV (Figure 4.6 C). TSCs were infected at MOI 1. Moderate but 
continuous BiTE expression over 96 hours was observed for TSC8 and TSC23. Continually 
increasing BiTE levels were observed in culture supernatants of TSC17. Highest BiTE levels 
were detected in supernatant of TSC17 96 hours post infection. Absorbance values in  remained 
at background level. 
Figure 4.6: BiTE secretion by MV-BiTE-infected cells. (A) SDS-PAGE: Vero cells were 
inoculated with serum-free medium (mock) or MV-BiTE at a multiplicity of infection (MOI) 
of 0.03. Cells culture supernatants were collected 63 h post infection and concentrated 20-fold. 
Proteins were separated by SDS-PAGE and stained with a coomassie R-250 dye-based reagent. 
The expected molecular weight for BiTE antibodies is approximately 55 – 58 kilodalton (kDa) 
(red boxes). (B) ELISA: Cells were infected with MV-mCD3xCEA at MOI 0.03 (Vero) or MOI 
1 (MC38 cells). (C) TSCs were infected with unmodified MV or MV-hCD3xCEA at MOI 1. 
Error bars represent standard deviation. (B, C) Cell culture supernatants were collected 24, 48, 
72 and 96 hours post infection and relative BiTE concentrations were determined by ELISA 
with recombinant human CEA. Absorbance values of BiTE-containing supernatants were 
normalized to medium only (mock) and are shown as fold change over mock. 
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4.3. Functional Characterization of MV-encoded BiTEs 
4.3.1. Purification of BiTEs Expressed by MV-infected Cells 
BiTEs were purified from culture supernatants of MV-BiTE-infected cells (vpBiTEs) to 
characterize BiTE functionality in vitro. Culture supernatants were sterile-filtered and BiTEs 
were purified by affinity chromatography using immobilized nickel-ion (Ni2+) spin columns. 
BiTEs were eluted from the Ni-columns by addition of imidazole. Imidazole in the eluate was 
washed out with PBS using centrifugal filter units with a vertical membrane that retains proteins 
with a molecular weight larger than 10 kDa. Different steps of the purification procedure were 
analyzed by Western blot using an anti-HA-tag antibody (Figure 4.7 A). BiTEs were not detectable 
in the flow through or washing fractions after the columns were loaded with BiTE-containing 
supernatant. Both elution fractions with different concentrations of imidazole contained BiTE 
antibodies. vpBiTEs were subjected to SDS-PAGE gel electrophoresis and subsequently stained 
with a coomassie dys. Clear bands of the expected band size were detected (Figure 4.7 B).  
Figure 4.7: Purification of BiTEs secreted by MV-BiTE-infected cells. (A) Vero cells were 
inoculated with MV-mCD3xCEA at a multiplicity of infection (MOI) of 0.03 in serum-free 
medium. Cell culture supernatant was collected 62 h post infection and purified by affinity 
chromatography. Different fractions of the purification procedure were analyzed by Western blot 
and BiTE was detected by anti-HA antibody. (B) Purified BiTEs were subjected to SDS-PAGE gel 
electrophoresis and quality of purification was analyzed by coomassie staining. 
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4.3.2. Binding Specificity of Purified BiTEs 
Binding specificity of MV-expressed vpBiTEs was evaluated using sandwich and competitive 
ELISAs, magnetic pull-down of BiTE-labeled cells and flow cytometry. First, specific binding 
of vpBiTEs to recombinant human CEA (rhCEA) and two control peptides (murine PD-L1 and 
CTLA-4) was assessed with sandwich ELISAs (Figure 4.8 A). Expectedly, the anti-CEA BiTEs 
bound to rhCEA, while there was no significant binding-specific signal detected using CD20-
targeting BiTEs. Concurrently, anti-CEA BiTEs did not bind to the two control peptides. For 
the competitive ELISAs, vpBiTEs were incubated with target cells and subsequently target cells 
were pelleted. Unbound BiTE remained in the supernatant, which was transferred on ELISA 
plates coated with the competing, cell-type specific recombinant protein (MC38-CEA: rhCEA, 
PBMCs: rhCD3). The more target antigen-expressing cells were incubated with BiTE, the less 
BiTE was detected in the supernatant (Figure 4.8 B). Binding specificity to target cells was 
compared to non-target cells (rhCEA: MC38) or mock controls (rhCD3: PBS). 
Figure 4.8: Evaluation of BiTE binding specificity by ELISAs. (A) Sandwich ELISA: 
Binding of CEA-targeting purified BiTEs to recombinant human CEA was analyzed. CD20-
targeting BiTEs and non-relevant protein (recombinant murine PD-L1 and CTLA-4) served as 
specificity controls. PBS was included as negative control. (B) Competitive ELISAs: Binding 
of purified BiTEs to cell-expressed target antigen was evaluated (MC38-CEA: human CEA, 
PBMCs: human CD3). Non-target cells or PBS served as internal controls. (A, B) Absorbance 
values were normalized to PBS or non-target cells and are shown as fold change over controls. 
Mean of triplicate samples with standard deviation is shown. Statistical analysis was performed 
by one-way ANOVA and p values were adjusted for multiple comparisons by Dunnett’s test. 
P
B
S
4x
10
^6
 P
B
M
C
s
5x
10
^5
 P
B
M
C
s
5x
10
^4
 P
B
M
C
s
0.0
0.5
1.0
1.5
hCD3xCEA
**
p=0.0153
p=0.0329
P
B
S
hC
D
3x
C
E
A
m
C
D
3x
C
EA
hC
D
3x
C
D
20
m
C
D
3x
C
D
20
hC
D
3x
C
E
A
hC
D
3x
C
E
A
fo
ld
 c
h
a
n
g
e
rh
C
E
A
rm
P
D
-L
1
rm
C
TL
A
-4
5x
10
^6
 M
C
38
5x
10
^6
 M
C
38
-C
E
A
5x
10
^5
 M
C
38
-C
E
A
5x
10
^4
 M
C
38
-C
E
A
0.0
0.5
1.0
1.5
mCD3xCEA
p=0.0011
A B 
4. Results 
 
60  
Furthermore, we investigated BiTE binding to cell-expressed target antigen by magnetic pull-
down of BiTE-bound target cells. vpBiTEs were incubated with target cells and free BiTE was 
removed. Remaining, cell-bound BiTEs were labeled with anti-HA-biotin antibodies and 
subsequently with anti-biotin magnetic beads. Labeled cells were separated from unlabeled 
cells by magnetic-activated cell sorting (MACS). Cells in the flow through (unlabeled cells) 
and eluted from the MACS columns (labeled cells) were lysed and analyzed by Western blot 
using anti-β-actin antibody (Figure 4.9). MC38-CEA cells were detected in the BiTE-labeled 
fractions, while there were no cells detectable in the corresponding fraction with MC38 cells. 
In all flow through fractions unlabeled cells were detectable. 
Figure 4.9: Magnetic pull-down of BiTE-labeled target cells. Binding of CEA-targeting 
BiTEs to MC38-CEA target cells was evaluated. Target cells were incubated with CEA-
targeting purified BiTEs. MC38 cells were included as specificity controls. BiTE-bound cells 
were magnetically labeled (via the BiTE N-terminal HA-tag) and separated from unlabeled 
cells on a MACS separator. Flow through and magnetically retained fractions were collected 
separately and lysed. Lysates were analyzed by Western blot using anti-β-actin antibody. Left 
panel: BiTE binding to cells in the magnetically retained fraction. Right panel: Unlabeled cells 
in the flow through fraction. Red print indicates the CEA-expressing target cells. 
 
The final BiTE binding test to cell-expressed target antigen was evaluated by flow cytometry 
(Figure 4.10). Human CD3-targeting BiTEs bound to CD3+ T cells within human peripheral 
blood mononuclear cells (PBMCs). Vice versa, murine CD3-targeting BiTEs bound to CD3+ 
T cells within murine splenocytes. Likewise, mCD3xCEA BiTE bound to MC38-CEA cells, 
but not to MC38 cells. Similarly, hCD3xCEA BiTE bound to CEA-expressing TSCs. The level 
of BiTE binding to TSCs correlated with the CEA-expression level, as determined by flow 
cytometric analysis using anti-CEA-PE antibody (Figure 4.10 D). 
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Figure 4.10: Flow cytometric analysis of BiTE binding. (A) Purified BiTEs were incubated 
with human PBMCs and murine splenocytes, respectively. BiTE binding to T cells was detected 
by anti-His-FITC antibody. (B) MC38-CEA cells were incubated with purified mCD3xCEA 
BiTE. MC38 cells served as specificity control. (C) Purified hCD3xCEA BiTEs were incubated 
with single-cell suspensions of TSC8, TSC17 or TSC23. (B, C) BiTE binding to tumor cells 
was detected by anti-HA-PE antibody. (D) Endogenous CEA-expression levels of TSCs were 
investigated using an anti-CEA-PE antibody. (A-D) Overlay histograms of detection and 
isotype antibodies are shown. Each peak is normalized to its mode. 
 
 
 
A B 
C 
D 
4. Results 
 
62  
4.3.3. BiTE-mediated T  Cell Cytotoxicity 
The potential of vpBiTEs to mediate T cell cytotoxicity was evaluated using lactate 
dehydrogenase (LDH) release assays. Therefore, vpBiTEs were added to co-cultures of tumor 
cells and T cells. BiTE-mediated T cell cytotoxicity was assessed by LDH release of lysed 
tumor cells and non-target tumor cells or control BiTEs were used as specificity controls. 
hCD3xCEA vpBiTE directed cytolytic activity of T cells within human PBMCs against MC38-
CEA cells in a concentration-dependent manner (Figure 4.11 A). Concurrently, hCD3xCD20 
BiTE-engaged T cells did not lyse MC38-CEA cells. Highest specific lysis of 52 – 59 % was 
observed at hCD3xCEA BiTE concentrations >100 ng/ml. 
T cells were isolated from murine splenocytes by negative selection (mTCs). mCD3xCEA 
vpBiTE mediated mTC cytotoxicity against MC38-CEA cells in a concentration-dependent 
manner, comparable to hCD3xCEA BiTE and human PBMCs (Figure 4.11 B). Highest specific 
lysis of 24 - 25 % was observed at mCD3xCEA BiTE concentrations >100 ng/ml. mCD3xCEA 
BiTE-engaged mTCs did not lyse non-target cells of the parental cell line MC38. Furthermore, 
Trp-2-specific murine cytotoxic T lymphocytes (mCTLs) were re-directed by mCD3xCEA 
vpBiTE to lyse Trp-2 negative MC38-CEA cells (Figure 4.11 C). Activated mCTLs 
demonstrated high specific lysis of 46 – 58 % over the entire range of tested effector to target 
cell (E:T) ratios, while MC38 cells were not lysed. 
hCD3xCEA vpBiTE also directed PBMC-derived human T cells against CEA-expressing TSCs 
(Figure 4.11 D). Specific lysis occurred in a concentration-dependent manner. Highest specific 
lysis was observed at 1 µg/ml hCD3xCEA (37 % TSC8, 40 % TSC17, 35 % TSC23). Notably, 
increased baseline levels of LDH release from TSCs in the presence of hCD3xCD20 vpBiTE 
were observed. However, these levels remained significantly lower compared to hCD3xCEA 
containing samples at BiTE concentrations >100 ng/ml. 
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Figure 4.11: BiTE-mediated T cell cytotoxicity in vitro. Purified BiTEs were added to co-
cultures of tumor cells and T cells. BiTE-mediated cytotoxicity was assessed by lactate 
dehydrogenase (LDH) release assays. (A) Human PBMCs were co-cultured with MC38-CEA 
cells at a ratio of 50:1. BiTEs were added at indicated concentrations. hCD3xCD20 BiTE served 
as specificity control. (B) Murine T cells (mTCs) isolated from splenocytes were co-cultured 
with MC38-CEA cells at a ratio of 12:1. mCD3xCEA BiTE was added at indicated 
concentrations. (C) Murine cytotoxic T lymphocytes (mCTLs) were co-cultured with MC38-
CEA cells at indicated ratios. mCD3xCEA BiTE was added at a concentration of 1 µg/ml. (B, 
C) MC38 cells were included as specificity controls. (D) Human PBMCs were co-cultured with 
TSCs at a ratio of 50:1. hCD3xCEA BiTE was added at indicated concentrations. hCD3xCD20 
BiTE served as specificity controls. (A-D) Mean of triplicate samples with standard deviation 
is shown. Statistical analysis was performed by two-way ANOVA and p values were adjusted 
for multiple comparisons by Sidak’s test.  
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Cytokines are a hallmark of T cell activation and cytotoxicity. Thus, we analyzed cytokines 
secreted by BiTE-engaged T cells in the supernatant of co-cultures with tumor cells. Cytokine 
concentrations were quantified using a cytokine bead array (CBA). Low cytokine levels (shown 
are IFN-γ, TNF and IL-2) were secreted by T cells isolated from murine splenocytes in the 
presence of MC38-CEA cells and mCD3xCEA vpBiTE (Figure 4.12 A). TNF levels in the 
supernatant were significantly increased, compared to supernatants from co-cultures with 
MC38 cells. Levels of IFN-γ and IL-2 were not significantly increased. T cells within human 
PBMCs secreted high levels of cytokines in co-cultures with TSCs and hCD3xCEA vpBiTE 
(Figure 4.12 B). Significantly increased levels of IFN-γ, TNF and IL-2 were detected, compared 
to co-cultures with hCD3xC20 vpBiTE. Highest cytokine levels were observed in co-cultures 
with TSC8. 
Figure 4.12: BiTE-mediated cytokine secretion by T cells in vitro. Purified BiTEs were 
added to co-cultures of tumor cells and T cells. Secreted cytokines were quantified by cytokine 
bead arrays. (A) Murine T cells isolated from splenocytes were co-cultured with MC38-CEA 
cells at a ratio of 50:1. mCD3xCEA BiTE was added at a concentration of 1 µg/ml. MC38-CEA 
cells served as specificity control. (B) Human PBMCs were co-cultured with indicated TSCs at 
a ratio of 50:1. hCD3xCEA BiTE was added at a concentration of 1 µg/ml. hCD3xCD20 BiTE 
served as specificity control. (A, B) Concentrations of IFN-γ, TNF and IL-2 in co-culture 
supernatants after 24 hours are shown. Mean of triplicate samples with standard deviation is 
shown. Statistical analysis was performed by two-way ANOVA and p values were adjusted for 
multiple comparisons by Sidak’s test. 
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4.4. Therapeutic Efficacy of MV-BiTE in Immunocompetent Mice 
The therapeutic potential of MVs encoding BiTEs was evaluated in the syngeneic tumor models 
of MC38-CEA and B16-CD20-CD46. Tumor cells were implanted subcutaneously into the 
right flanks of immunocompetent C57BL/6 mice. When tumors reached a mean volume of 40-
50 mm3, mice were treated with intratumoral injections of 1x106 ciu of MV-BiTE or carrier 
fluid (OptiMEM) on four or five consecutive days (n = 20 per group). Tumor progression and 
survival of mice was followed for 10 mice per group. Endpoints were defined as tumor volumes 
of >1,000 mm3, tumor diameter > 15 mm, tumor ulceration, tumor bleeding or severe signs of 
illness. Mice fulfilling one or more of the predefined endpoints were sacrificed. Furthermore, 
10 mice per group were sacrificed 24 hours after the last treatment to analyze treatment-related 
immunostimulatory effects. 
In the MC38-CEA model, efficacy of MV encoding the CEA-targeting BiTE was compared to 
MV-mCD3xCD20 and mock treatment (carrier fluid) (Figure 4.13). Both MV-BiTE treatments 
prolonged survival as compared with survival of mock-treated mice. On day 10 after tumor 
implantation, the first mouse (mock treatment group) was sacrificed because of tumor 
ulceration with a tumor volume of 227 mm3. The mean tumor volume of mock-treated mice on 
day 10 was 105 mm3. Tumor growth of mice treated with MV-BiTE was delayed and reached 
volumes of 60 mm3 (MV-mCD3xCEA) and 44 mm3 (MV-mCD3xCD20) on day 10 post 
implantation (Figure 4.13 A). Median survival (5/10 mice alive) of mock-treated mice was 15 
days, compared to 41 days for mice treated with MV-mCD3xCD20. Median survival for mice 
treated with MV-mCD3xCEA was not reached. 7/10 mice treated with MV-mCD3xCEA 
experienced durable remissions, compared to 4/10 mice treated with MV-mCD3xCD20 and 
0/10 mock-treated mice. Frequencies of reached endpoints were 16 % tumor volume and 84 % 
tumor ulceration. MV-BiTE treatments led to significantly prolonged survival with p < 0.001 
for MV-mCD3xCEA and p < 0.01 for MV-mCD3xCD20, as compared to mock treatment. 
However, survival of MV-mCD3xCEA-treated mice was not significantly prolonged compared 
to MV-mCD3xCD20-treated mice. 
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Figure 4.13: Therapeutic efficacy of MV-BiTE against murine MC38-CEA. 1x106 MC38-
CEA cells were subcutaneously implanted into the flank of C57BL/6 mice. Mice were treated 
with intratumoral injections of carrier fluid (mock) or 1x106 cell infectious units of indicated 
MV-BiTE on days 4, 5, 6, and 7 post implantation (n = 10 mice/group). (A) Tumor volumes of 
individual mice 10 days post implantation. Mean values with standard deviations are indicated. 
(B) Kaplan-Meier survival analysis. Log-rank (Mantel-Cox) test was performed for statistical 
comparison of survival curves and p values were corrected for multiple comparisons by the 
Bonferroni method. 
 
In the B16-CD20-CD46 model, efficacy of MV-mCD3xCD20 was compared to MV-
mCD3xCEA, unmodified MV and mock (carrier fluid) (Figure A.3).* Treatment with MV-
mCD3xCEA and unmodified MV similarly prolonged survival, as compared with mock 
treatment. Median survival of mock-treated mice was 16.5 days, compared to 23.5 days for 
mice treated with MV-mCD3xCEA and 25 days for mice treated with unmodified MV. In this 
model, treatment with MV-mCD3xCD20 significantly prolonged survival, compared to 
treatment with MV-mCD3xCEA (p < 0.05, median survival: 30 days). Interestingly, treatment 
with purified BiTE only did not result in prolonged survival, compared to mock treatment 
(median survival: 18 days vs. 15 days). However, treatment with UV-inactivated MV-
mCD3xCD20 showed similar therapeutic effects as treatment with non-irradiated MV-
mCD3xCD20 (p < 0.001 compared to purified BiTE treatment, respectively) (Figure A.4).† 
Furthermore, MV-mCD3xCD20 treatment conferred protective antitumor immunity against the 
parental cell line B16 (Figure A.5).‡ 
                                                 
*
 Results generated by Johannes Heidbüchel 
†
 Results generated by Johannes Heidbüchel 
‡
 Results generated by Tobias Speck 
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Plasma levels of BiTE in peripheral blood of MC38-CEA-bearing mice treated with MV-BiTE 
were analyzed to assess systemic exposure of injected or de novo synthesized BiTE. Blood was 
drawn 2 hours and 24 hours after the fourth treatment. Blood plasma was analyzed by ELISA 
with recombinant human CEA. BiTE plasma levels in MV-BiTE-treated mice were not 
elevated, as compared to mock-treated mice (Figure 4.14). 
Figure 4.14: BiTE plasma levels after MV-BiTE treatment of MC38-CEA-bearing mice. 
MC38-CEA cells were subcutaneously implanted into the flank of C57BL/6 mice. Mice were 
treated with intratumoral injections of carrier fluid (mock) or indicated MV-BiTE on four 
consecutive days. (A) Purified mCD3xCEA BiTE was titrated and analyzed by ELISA with 
recombinant human (rh)CEA. (B) Blood was drawn from MC38-CEA-bearing mice 2 and 24 
hours after the fourth treatment. Blood plasma was analyzed by ELISA with rhCEA of the 
indicated treatment groups (n = 3-5 mice/group). (A, B) Absorbance values were normalized to 
PBS and are shown as fold change over PBS. Mean of three to five samples with standard 
deviation is shown. 
 
4.4.1. Analysis of MV-BiTE Mediated Immunostimulatory Effects 
Tumor-infiltrating lymphocytes (TILs) and intratumoral cytokine concentrations were analyzed 
to investigate the immunostimulatory effects mediated by MV-BiTE treatment. Tumors from 
10 mice per group were explanted 24 hours after the last day of treatment (as described in 
chapter 4.4). Explanted tumors were processed to single-cell suspensions and prepared for 
analysis of TIL differentiation and activation by flow cytometry (Figure 4.15 A). The gating 
strategy is shown in Figure A.6. Notably, high percentage of lymphocytes were found in MC38-
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CEA tumors of all treatment groups, including mock treatment. Increased percentage of 
lymphocytes were found in MV-BiTE-treated tumors (MV-mCD3xCEA: 33 % of live cells, 
MV-mCD3xCD20: 35 % of live cells), as compared with mock-treated tumors (28 % of live 
cells). However, only MV-mCD3xCD20 treatment significantly increased percentage of 
infiltrating lymphocytes (p = 0.0113). The ratio of CD8+ to CD4+ T cells was approximately 
2-fold higher for both MV-BiTE treatment groups, as compared with mock treatment. At the 
same time, the expression of the activation marker CD69 on CD8+ T cells was increased after 
MV-BiTE treatment, compared to mock treatment (60-61 % vs. 54 %) and the differentiation 
marker CD25 on CD4+ T cells was decreased (32-38 % vs. 48 %). Notably, most changes in 
TIL populations, activation or differentiation remained statistically not significant. 
In contrast, less lymphocytes than 1 % of live cells were detected in mock-treated B16-CD20-
CD46 tumors (Figure A.7).* Subtle elevated percentage of lymphocytes were found in MV-
mCD3xCEA-treated tumors (4 %, 0.7 to 9 % of live cells) and significantly increased numbers 
after MV-mCD3xCD20 treatment (16 %, 2.5 to 46 % of live cells, p = 0.0003), as compared 
with mock treatment. The CD8+ to CD4+ T cell ratio of 1.2 in mock-treated tumors was similar 
to the ratio found in mock-treated MC38-CEA tumors. The ratio was increased for MV-
mCD3xCEA-treated B16-CD20-CD46 tumors (ratio of 2.9) and significantly increased after 
MV-mCD3xCD20 treatment (ratio of 8.8). 
Intratumoral concentrations of specific cytokines were analyzed by CBA assays. Protein levels 
of IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-17A were simultaneously quantified in tumor 
samples to investigate the expression of Th1, Th2, or Th17 cytokines. In the MC38-CEA model, 
increased levels of IFN-γ were obtained in MV-BiTE-treated tumors (Figure 4.15 B). However, 
significantly increased levels of IFN-γ were obtained only in MV-mCD3xCD30-treated tumors. 
Levels of IL-2, IL-4, IL-6, IL-10, TNF, and IL-17A in MV-BiTE-treated tumors were elevated 
as well, however were not significantly increased, as compared with mock-treated tumors. In 
general, highest cytokine levels were detected in MV-mCD3xCD20-treated tumors. Except for 
IL-10 concentrations, which was highest for MV-mCD3xCEA-treated tumors. 
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Figure 4.15: Immunostimulatory effects of MV-BiTE treatment in MC38-CEA bearing 
mice. MC38-CEA cells were subcutaneously implanted into the flank of C57BL/6 mice. Mice 
were treated with intratumoral injections of carrier fluid (mock) or the indicated MV-BiTE on 
four consecutive days. Tumors were explanted one day after the last treatment. (A) Analysis of 
tumor-infiltrating lymphocytes (TILs). Single-cell suspensions were prepared for flow 
cytometric analysis of TIL subpopulations (n = 10 mice/group). Mean values with standard 
deviation are shown. Statistical analysis was performed by one-way ANOVA and p values were 
adjusted for multiple comparisons by Tukey’s test. (B) Cytokine profiles of MV-BiTE-treated 
mice. Intratumoral cytokines were quantified by cytokine bead arrays. Mean values with 
standard deviation are shown. Statistical analysis was performed by two-way ANOVA and p 
values were adjusted for multiple comparisons by Dunnett’s test. 
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In the B16-CD20-CD46 model, intratumoral cytokine concentrations after mock, MV-
mCD3xCD20 and MV-mCD3xCEA treatment were assessed (Figure A.8).* Both MV-BiTE 
treatments significantly increased levels of IFN-γ, as compared with mock treatment (p < 
0.0001). In addition, TNF concentrations in MV-mCD3xCD20-treated tumors were 
significantly increased, compared to mock-treated tumors (p = 0.0015). In general, elevated 
cytokine concentrations were found in MV-BiTE-treated tumors, as compared with mock-
treated tumors, except for IL-6 concentrations. 
 
4.5. Therapeutic Efficacy of MV-BiTE in TSC Xenografts 
The therapeutic efficacy of MV-BiTE against CEA-expressing human colon cancer xenografts 
was evaluated. Single-cell suspensions of 1x106 TSC8, TSC17 and TSC23 were implanted 
subcutaneously into the right flanks of immunocompromised NSG mice. Efficacy of MV-
hCD3xCEA with the transfer of PBMCs was compared to mock, PBMCs only and MV-
hCD3xCEA only treatments. Beforehand, healthy donor-derived PBMCs were tested for 
alloreactive T cell responses against the TSCs in vitro and non-reactive donors were selected. 
When tumors reached a mean volume of 100 mm3, mice received intratumoral injections of 
1x106 ciu MV-hCD3xCEA on four consecutive days. On the first day of treatment, mice 
additionally received 1x107 healthy donor-derived PBMCs or carrier fluid (PBS) 
intratumorally. Notably, TSC17-bearing mice received only 3.3x106 PBMCs due to an 
unexpectedly low-yield in PBMC isolation. Tumor progression and survival were followed for 
10 mice per group. Predefined endpoints were tumor volumes of >1,000 mm3, tumor diameter 
of > 15 mm, tumor ulceration, tumor bleeding or severe signs of illness. 
Treatment with MV-hCD3xCEA only significantly prolonged survival of TSC8-bearing NSG 
mice, as compared to treatments with mock or PBMCs only (p < 0.001) (Figure 4.16 A, B). 
Treatment with MV-hCD3xCEA and the transfer of PBMCs significantly prolonged survival, 
as compared to treatment with MV-hCD3xCEA only (p < 0.01). The first mouse (treatment 
with PBMCs only) was sacrificed on day 17 after TSC8 implantation with a tumor volume of 
1,023 mm3. On day 17, the mean tumor volume of mice treated with PBMCs only was largest 
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with 596 mm3, compared to 345 mm3 (mock), 237 mm3 (MV-hCD3xCEA only) and 144 mm3 
(MV-hCD3xCEA + PBMCs) (Figure 4.16 A). Median survival of mock-treated mice was 22 
days, compared to 20 days (PBMCs only), 36 days (MV-hCD3xCEA only) and 64 days (MV-
hCD3xCEA + PBMCs) (Figure 4.16 B). Individual tumor growth curves are shown in Figure 
4.17 A. Reached endpoints were tumor volume (90 %) and tumor diameter (10 %). 
For the TSC17 xenograft model, treatment with MV-hCD3xCEA only did not prolong survival 
and transfer of PBMCs only even significantly shortened survival as compared to mock 
treatment (p < 0.05). However, treatment with MV-hCD3xCEA and the transfer of PBMCs 
prolonged survival, compared to mock treatment (statistically not significant) (Figure 4.16 D). 
First mice reached the tumor diameter endpoint on day 33 after TSC17 implantation (mock 
treatment and PBMCs only). Mean tumor volumes on day 33 were 402 mm3 (mock), 617 mm3 
(PBMCs only), 313 mm3 (MV-hCD3xCEA only) and 293 mm3 (MV-hCD3xCEA + PBMCs) 
(Figure 4.16 C). Median survival of mock-treated mice was 48 days, compared to 39.5 days 
(PBMCs only), 52.5 days (MV-hCD3xCEA only) and 66.5 days (MV-hCD3xCEA + PBMCs). 
Individual tumor growth curves are shown in Figure 4.17 B. The frequencies of reached 
endpoints were 67 % tumor volume and 33 % tumor diameter. 
In the TSC23 model, treatment with MV-hCD3xCEA only significantly prolonged survival, as 
compared with mock treatment (p < 0.01) (Figure 4.16 E, F). Treatment with PBMCs only did 
neither significantly prolong nor shorten survival, compared to mock treatment and MV-
hCD3xCEA only. Notably, 50 % of TSC23-bearing mice treated with PBMCs only developed 
graft-versus-host disease (GvHD). Mice suffering from GvHD showed severe signs of illness, 
which coincided with tumor shrinkage. However, treatment with MV-hCD3xCEA with the 
transfer of PBMCs significantly prolonged survival, as compared to treatment with MV-
hCD3xCEA only (p < 0.001). Interestingly, no mice treated with MV-hCD3xCEA with the 
transfer of PBMCs developed GvHD. On day 19 after TSC23 implantation, the first mouse 
from the mock treatment group reached the tumor volume endpoint with 1,082 mm3. The mean 
tumor volume of mock-treated mice on day 19 was 514 mm3. Again, the mean tumor volume 
of mice treated with PBMCs only was largest with 533 mm3, as compared to mock-treated mice, 
MV-hCD3xCEA only (309 mm3) and MV-hCD3xCEA with the transfer of PBMCs (166 mm3) 
(Figure 4.16 E). Median survival after mock treatment was 28 days, compared to 36 days 
(PBMCs only), 41 days (MV-hCD3xCEA only) and 65.5 days (MV-hCD3xCEA + PBMCs) 
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(Figure 4.16 F). Individual tumor growth curves are shown in Figure 4.17 C. The frequencies 
of reached endpoints were 57 % tumor volume, 27 % tumor diameter and 17 % severe signs of 
illness. 
Figure 4.16: Therapeutic efficacy of MV-BiTE against human colon cancer xenografts. 
1x106 tumor spheroid cultures (TSCs) were subcutaneously implanted into the flank of NSG 
mice. Mice were treated with intratumoral injections of carrier fluid (mock) or 1x106 cell 
infectious units of MV-hCD3xCEA on four consecutive days (n = 9-10 mice/group). On the 
first day of treatment, TSC8- and TSC23-bearing mice additionally received an intratumoral 
transfer of 1x107 human PBMCs. TSC17-bearing mice received a transfer of 3.3x106 PBMCs. 
(A, C, E) Tumor volumes of individual mice. On day 17 (TSC8), day 33 (TSC17) or day 19 
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(TSC23) post implantation first tumors reached one of the predefined endpoints and the 
respective mice were sacrificed. Mean values are indicated. (B, D, F) Kaplan-Meier survival 
analyses. Statistical comparison between MV-BiTE with the transfer of PBMCs and MV-BiTE 
only treatment groups is indicated in the graphs. Log-rank (Mantel-Cox) test was performed for 
statistical comparison of survival curves and p values were corrected for multiple comparisons 
by the Bonferroni method. 
 
Figure 4.17: Individual tumor growth of MV-BiTE-treated human colon cancer 
xenografts. Tumor spheroid cultures (TSCs) were implanted subcutaneously into the flank of 
NSG mice. When tumors reached a mean volume of 100 mm3, mice were treated with 
intratumoral injections of carrier fluid (mock) or MV-hCD3xCEA on four consecutive days (n 
= 9-10 mice/group). On the first day of treatment, TSC8- and TSC23-bearing mice additionally 
received an intratumoral transfer of 1x107 human PBMCs. TSC17-bearing mice received a 
transfer of 3.3x106 PBMCs. (A-C) Individual tumor growth curves of (A) TSC8-bearing mice, 
(B) TSC17-bearing mice and (C) TSC23-bearing mice. Initiation of treatment is indicated by 
blue arrows and lines. 
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In general, no signs of BiTE-related toxicities were observed. BiTE plasma levels in peripheral 
blood of mice treated with MV-BiTE were evaluated 24 hours after the fourth treatment and 
compared to PBMCs only-treated mice and the BiTE content of one dose MV-hCD3xCEA. 
BiTE plasma levels of MV-BiTE-treated mice remained below detection limit (Figure 4.18). 
Figure 4.18: BiTE plasma levels after treatment of TSC23-bearing mice with MV-BiTE. 
TSC23 cells were implanted subcutaneously into the flank of NSG mice. Mice were treated 
with intratumoral injections of carrier fluid (mock) or MV-hCD3xCEA on four consecutive 
days. On the first day of treatment, mice additionally received an intratumoral transfer of 1x107 
human PBMCs. (A) Purified hCD3xCEA BiTE was titrated and analyzed by ELISA with 
recombinant human (rh)CEA. (B) Blood was drawn from TSC23-bearing mice 24 hours after 
the fourth treatment. Blood plasma was analyzed by ELISA with rhCEA for the indicated 
treatment groups (n = 5 mice/group). (A, B) Absorbance values were normalized to PBS and 
are shown as fold change over PBS. 
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5. Discussion 
5.1. The Promise of Cancer Immunovirotherapy 
The primary choice of treatment for many patients with localized tumor diseases remains 
surgery (158). For non-localized tumor diseases, systemic cancer therapies are required such as 
cytotoxic chemotherapy, hormonal agents or targeted therapy (159). However, long-term 
treatment success is limited to a minority of patients or to a few tumor diseases with particular 
mutations. In recent years, immunotherapy has become a major field of research in modern 
oncology. Immune checkpoint inhibitory antibodies, adoptive T cell therapies and vaccines 
have provided proof for the therapeutic potential of our body’s immune system to fight cancers 
(160). 
Oncolytic viruses (OVs) selectively infect and lyse tumor cells, which can result in massive 
tumor debulking (132, 152, 153, 161-165). Besides direct oncolysis, OVs have been recognized 
as potent immunostimulatory agents in the past decade (166). The immunostimulatory effects 
of the viral infection and oncolytic “in situ vaccination” may even induce systemic antitumor 
immunity (166). This promise of natural and genetically engineered OVs is currently being 
explored in clinical studies worldwide (96, 167-180). Noteworthy, most genetic modifications 
aim to support the immunostimulatory activity of OVs by expression of transgenes, which 
encode for cytokines such as GM-CSF, IFN-β, IL-12 or tumor-associated antigens (chapter 
1.4.1 and references therein). 
This study reports on oncolytic measles viruses, which were engineered to encode bispecific T 
cell engaging antibodies (MV-BiTE). On the one hand, oncolytic MVs have been described to 
induce an immunogenic cell death (ICD) (181-183). On the other hand, BiTEs simultaneously 
engage local T cells and tumor cells and thereby activate the engaged T cells. Besides bystander 
tumor lysis, BiTE-engaged T cells have been described to secrete cytokines, which support the 
establishment of an antitumor immune response (chapter 1.3.4 and references therein). Thus, 
tumor-restricted expression of BiTEs may synergize with the oncolytic viral vector. This study 
demonstrates that therapeutic efficacy of oncolytic MVs can be enhanced by encoding BiTEs 
within the viral genome. To this end, immunocompetent mouse models and patient-derived 
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xenografts with the transfer of human PBMCs were employed to study MV-BiTE efficacy, 
mode of action and safety aspects. 
 
5.2. Recombinant BiTE-Encoding Measles Viruses 
A recombinant MV clone generated from cDNA of the Edmonston B vaccine strain was used 
in this study to investigate the therapeutic efficacy of MV-BiTE. Compared to other MV 
vaccine strains, such as Schwarz/Moraten or Zagreb, the original Edmonston B vaccine strain 
is less attenuated (184). However, the recombinant MVs derived from the Edmonston B vaccine 
strain have been reported to be less immunogenic in immunocompetent mice expressing human 
CD46, as compared with recombinant MVs derived from Schwarz strain (185). Reduced 
immunogenicity is probably a result of acquired genetic alterations. Sequence comparisons of 
different MV genomes revealed that viruses derived from the recombinant Edmonston B cDNA 
genetically diverged from the original Edmonston B vaccine strain (185). Several amino acid 
substitutions have occurred in the P/V/C proteins, which might influence viral interferon 
defense mechanisms and thereby affect viral replication. However, a reduced immunogenicity 
of the vector might delay viral clearance by the immune system and thus increase expression 
of the delivered transgene. Whether one particular recombinant MV vaccine strain is superior 
over the other strains in terms of therapeutic efficacy has not been analyzed systematically to 
date. Presumably, it cannot be generalized due to inter-individual differences in the patient’s 
immune system and the tumor interferon status (186). On the on hand, recombinant MVs 
derived from the Edmonston B vaccine strain might be beneficial in tumors with highly 
attenuated antiviral defense mechanisms, if the encoded transgene requires higher local 
concentrations. On the other hand, recombinant MVs derived from the Schwarz vaccine strain 
might be beneficial in tumors with less attenuated antiviral defense mechanisms in order to 
effectively replicate. However, the more immunogenic Schwarz strain-derived MVs might be 
cleared by the immune system prematurely, which limits transgene expression. 
The BiTE-encoding sequence lengths are approximately 1,600 base pairs. A previous study by 
Engeland et al. investigated the therapeutic efficacy of MVs encoding anti-CTLA-4 and anti-
PD-L1 dimeric antibodies with a similar sequence length (92). Rescue of viral particles was not 
successful if the anti-CTLA-4 antibody sequence was inserted upstream of the N open reading 
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frame (ORF) and downstream of the P ORF, respectively. These insertion sites would result in 
strong transgene expression (187) and have been used to study MVs encoding smaller 
transgenes, such as cytokines and prodrug convertases (76, 78, 188-190). However, insertion 
of the antibody sequence downstream of the H ORF finally resulted in the formation of viral 
particles. Thus, BiTE-encoding sequences were as well inserted into an additional transcription 
unit (ATU) downstream of the H ORF. Rescue of viral particles was successful for all BiTE-
encoding constructs (BiTEs: hCD3xCEA, mCD3xCEA, hCD3xCD20, mCD3xCD20). 
Oncolytic efficacy depends on the dose of virus administration, which is limited for some 
oncolytic viruses by manufacturing issues, including MVs (191). Propagation of MV-BiTE 
resulted in titers of approximately 5x107 (+/- 3x107) cell infectious units (ciu)/ml and typically 
20 – 25 ml of virus suspension were obtained from the third passage. The total amount of 
approximately 1x109 ciu of MV-BiTE concentrated in 20 – 25 ml virus suspension was 
sufficient to conduct in vivo experiments. Transgene expression and oncolytic activity depend 
on viral replication. Therefore, virus growth kinetics of the individual MV-BiTE constructs 
were assessed and compared to unmodified MV. Importantly, replication of MV-BiTE was not 
impaired by encoding the additional transgene. Thus, similar cytopathic effects of MV-BiTE 
were expected and demonstrated in cell viability assays (XTTs). 
 
5.3. Mouse Models to Study Therapeutic Efficacy of MV-BiTE 
In general, murine cells are not susceptible to MV infection because they lack expression of 
MV entry receptors. There is no known murine homologue of human CD46 and the MV H 
protein is unable to bind to mouse SLAMF1 (143). Non-human primate cells expressing mouse 
nectin-4 are susceptible to MV infection, however infection is much less efficient in terms of 
infection rates, viral spread and the production of viral progeny, as compared to the respective 
cells expressing the human homologue (121). MV particles are able to enter murine MC38-
CEA cells at a very low rate (Figure 4.2 B MC38-CEA), probably by receptor-independent 
mechanisms such as macropinocytosis (192). To generate more susceptible murine cell lines, 
MC38-CEA and B16-CD20 cells were stably transduced to express human CD46 using 
lentiviruses. B16-CD20-CD46 and MC38-CEA-CD46 were susceptible to MV infection and 
produced higher virus titers than compared with the respective parental cell lines. Still, murine 
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cells expressing human CD46 are less permissive for MV infection, as compared to Vero cells, 
probably, because MV has been adapted to efficiently replicate in human cells (193, 194). 
Furthermore, the MV accessory proteins C and V might be less efficient in antagonizing mouse 
IFN activity (195). Unfortunately, implanted MC38-CEA-CD46 cells were rejected by 
immunocompetent C57BL/6J mice. Interestingly, B16-CD20-CD46 tumor growth in 
C57BL/6J mice was unimpaired. MC38 is a chemically induced murine tumor model, which 
acquired many immunogenic mutations (196). The B16 tumor model spontaneously arose in a 
C57BL/6 mouse under the surveillance of an intact immune system (197). Thus, the MC38 
tumor model per se is much more immunogenic than the B16 tumor model (198). The 
immunogenic nature of MC38 cells in combination with the expression of human CEA and 
human CD46 results in frequent tumor rejection while B16-CD20-CD46 tumor growth is 
immunologically tolerated. 
As discussed above, there are major limitations to the MC38-CEA model in terms of MV 
infection, replication and thus transgene expression. However, it is essential to use 
immunocompetent models in order to study the effects mediated by an immunomodulatory 
drug. MV-BiTE demonstrated oncolytic activity against MC38-CEA in vitro (Figure 4.4). 
Supported by these results and because of a lack of an alternative syngeneic CEA-expressing 
mouse model, we decided to use MC38-CEA to investigate the therapeutic potential of MV-
BiTE in vivo. In addition, we established patient-derived, CEA-expressing xenografts of tumor 
spheroid cultures (TSCs) with the transfer of unstimulated human PBMCs. On the one hand, 
this model neglects the complex interplay between the immune system, MV-BiTE and the 
immune contexture of the tumor microenvironment (TME) (type, function, density and 
organization of immune cells (199)). On the other hand, the humanized model more adequately 
reflects the MV-BiTE pharmacodynamics and –kinetics in terms of oncolytic activity, viral 
capability to replicate and spread, and de novo synthesis of the MV-encoded transgene.  
 
5.4. Characterization of MV-Encoded BiTEs 
Transgene expression and secretion by MV-BiTE-infected cells was validated on mRNA and 
protein level, respectively. Supernatants of MV-BiTE-infected cells were harvested and BiTEs 
were purified to enrich BiTE concentrations and to remove contaminants such as host cell-
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derived proteins or nucleic acids. Notably, purification efficiency of BiTEs varied from batch 
to batch, which was monitored by Coomassie Blue stainings. The purification efficiency was 
dependent on the complexity of the culture medium. The more syncytia burst prematurely and 
“contaminated” the supernatant, the less efficient was the purification procedure. Therefore, 
indicated BiTE concentrations are not absolute but rather reflect the total protein content, 
including protein contaminations (estimated to 2 – 15 % contaminants by Coomassie Blue 
stainings). 
Binding of vpBiTE to target antigen was validated by a variety of assays, including ELISAs, 
magnetic pull-down of BiTE-labeled cells and flow cytometry. Specificity of BiTE binding was 
controlled by non-relevant recombinant protein or the respective parental cell lines, which do 
not express the relevant tumor-associated antigen. Binding specificity was verified within the 
context of the selected specificity controls. Functionality of vpBiTEs was validated in LDH 
release assays. Therefore, vpBiTEs were added to co-cultures of immune cells and tumor cells. 
Tumor cells were lysed with lysis solution to assess the maximum release of LDH to define 100 
% lysis. However, a limitation of the LDH release assay is the long incubation time of 24 to 48 
hours. On the one side, tumor cells in the maximum LDH release control wells approximately 
doubled after 24 hours and doubled twice after 48 hours, respectively. On the other side, tumor 
cells in the experimental wells were lysed by BiTE-engaged T cells and thus, did not replicate. 
Expectedly, only 50 % specific lysis could be reached after 24 hours incubation time and 25 % 
specific lysis after 48 hours incubation time. The chromium release assay is a similar assay 
format to assess T cell cytotoxicity. Only the amount of chromium, which was incorporated by 
tumor cells in the first place can be released and measured. Thus, maximum chromium release 
is independent of tumor cell proliferation. On the downside, the assay setup is more elaborate 
and working with the radioactive chromium isotope Cr51 constitutes an additional safety hazard.  
BiTE-mediated cytokine secretion by T cells in co-cultures with tumor cells was quantified 
using a cytometric bead array (CBA). In supernatants from both, murine splenocytes and human 
PBMCs, elevated levels of TH1 cytokines were found. In support of these results, other studies 
have reported the secretion of TH1 cytokines by BiTE-engaged T cells, as well (34, 37, 200, 
201). TH1 cytokines mediate pro-inflammatory effects and cellular immunity. Thus, a TH1 
polarized immune response may improve efficacy of anticancer immunotherapeutics (202, 
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203). Conclusively, this study demonstrates for the first time the feasibility to encode and 
express functional BiTE antibodies by negative-strand RNA viruses.  
 
5.5. Therapeutic Efficacy of MV-BiTE 
MV-BiTE treatment significantly prolonged survival of MC38-CEA-bearing mice. However, 
there was no significant difference between the treatment with MVs encoding the CEA-
targeting and the CD20-targeting BiTE, respectively. Furthermore, MV-mCD3xCEA treatment 
did not significantly increase numbers, activity or cytokine expression of tumor-infiltrating 
lymphocytes (TILs), as compared to MV-mCD3xCD20 treatment. Apparently, the therapeutic 
effects resulted from MV oncolytic activity and/or from MV immunogenicity. B16-CD20-
CD46 cells are more susceptible to MV infection. Thus, if the observed therapeutic effects in 
the MC38-CEA model resulted from MV oncolytic activity, we would expect enhanced 
efficacy in the B16-CD20-CD46 model. Again, MV-BiTE treatment significantly prolonged 
survival of B16-CD20-CD46-bearing mice. However in the B16-CD20-CD46 model, MV-
mCD3xCD20 treatment significantly prolonged survival of mice, as compared to treatment 
with unmodified MV or MV-mCD3xCEA. Along the same lines, MV-mCD3xCD20 treatment 
significantly increased the number of TILs, mostly CD8+ T cells. Apparently, in the B16-
CD20-CD46 model the CD20-targeting BiTE improved therapeutic efficacy of MV treatment. 
To further delineate the MV- and BiTE-mediated effects, we next treated B16-CD20-CD46-
bearing mice with UV-inactivated MV-BiTE to abolish viral replication while the functionality 
of BiTE, which is present in the virus suspension, is not compromised (Figure A.9). 
Importantly, we did not purify the propagated recombinant MVs. The shear sensitivity and 
pleomorphic nature of MVs results in low recovery and purity of infectious particles after 
ultracentrifugation or diafiltration (204). For use in humans, a tangential flow filtration system 
(Spectrum Laboratories, Inc., CA, USA) has been developed to purify and concentrate measles 
viruses in accordance with good manufacturing practices (205). In the present study, injections 
of MV-BiTE always contains MV-BiTE and BiTE antibodies, which have been expressed by 
the MV-BiTE-infected producer cell line. Interestingly, treatment with UV-inactivated MV-
mCD3xCD20 resulted in similar therapeutic effects, as compared to treatment with replication 
competent MV-mCD3xCD20. Thus, MV oncolytic activity is apparently not essential in the 
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syngeneic mouse models. Furthermore, treatment with purified mCD3xCD20 BiTE alone did 
not result in a meaningful therapeutic effect. Thus, the combination of the immunostimulatory 
effects of the replicating or non-replicating viral vector and BiTE treatment seems to recruit 
and activate further TILs or to stimulate local TILs to proliferate. Furthermore, MV-
mCD3xCD20 treatment conferred protective antitumor immunity against the parental cell line 
B16. This human CD20/CD46-independent immunity indicates, that BiTE-mediated T cell 
cytotoxicity may lead to epitope spreading, which is supported by literature (206, 207). 
Interestingly, the immunogenic MC38-CEA model harbors substantially higher numbers of 
TILs, as compared to the poorly immunogenic B16-CD20-CD46 model (mock-treated tumors: 
28 % of CD3+ cells of live cells versus less than 1 % of CD3+ cells of live cells). Mock-treated 
MC38-CEA tumors developed aggressively, despite the high numbers and activation status of 
TILs. Apparently, the TME is highly immunosuppressive and treatment with MV-mCD3xCEA 
could not induce antitumor immunity. Probably, the mode of action of BiTE-mediated T cell 
activation is not beneficial in this model. Noteworthy, therapeutic efficacy of MVs encoding 
GM-CSF, anti-PD-L1 antibody or IL-12 against MC38-CEA tumors has been demonstrated in 
previous studies (76, 78). Of note, these studies used MVs retargeted to CEA (MV-anti-CEA) 
to establish susceptibility of MC38-CEA to MV-anti-CEA infection. Therapeutic efficacy of 
MV-anti-CEA encoding GM-CSF, anti-PD-L1 antibody or IL-12 was enhanced, as compared 
to the unmodified MV-anti-CEA encoding eGFP or the antibody constant region IgG-Fc. Thus, 
therapeutic efficacy must have been dependent on the mode of action of the encoded transgenes. 
Moreover, Veinalde et al. compared efficacy of CEA-targeted and non-targeted MVs encoding 
IL-12 (208). Interestingly, she obtained similar results for both viruses in terms of survival.  
Apparently, IL-12, as well as GM-CSF and anti-PD-L1 antibody, were able to counteract 
immunosuppression or T cell exhaustion and established antitumor immunity in the MC38-
CEA model. In addition, considering the effects mediated by UV-inactivated MV-BiTE in the 
B16-CD20-CD46 model, these results support our hypothesis, that MV oncolytic activity might 
not be essential for therapeutic efficacy in the syngeneic mouse models. 
In the patient-derived xenografts, MV-hCD3xCEA treatment with the transfer of human 
PBMCs prolonged survival of TSC-bearing NSG mice. Noteworthy, PBMCs were freshly 
isolated, neither pre-activated nor enriched for T cells. Furthermore, mice received only one 
transfer of PBMCs at the first day of treatment and no recombinant human cytokines were co-
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administrated, which can be used to supported T cell expansion (209, 210). Still, MV-
hCD3xCEA treatment with the transfer of PBMCs significantly prolonged survival of TSC8- 
and TSC23-bearing mice, as compared to MV-hCD3xCEA treatment alone. Survival of 
TSC17-bearing mice was prolonged as well, however statistically not significant, as compared 
to MV-hCD3xCEA treatment only. Of note, due to an unexpectedly low yield in PBMC 
isolation, TSC17-bearing mice only received 1/3 of the amount of PBMCs transferred to TSC8- 
and TSC23-bearing mice, respectively. Thus, the transfer of more PBMCs may have enhanced 
therapeutic efficacy of MV-BiTE treatment of TSC17-bearing mice. 
For all three TSC xenografts, MV-BiTE treatment only delayed tumor growth, as compared to 
tumor growth of mock-treated mice. Interestingly, the transfer of PBMCs only increased mean 
tumor volumes, as compared to tumor volumes of mock-treated mice. Most likely, PBMCs did 
not promote tumor progression but rather caused an inflammatory swelling, which has been 
described for skin transplantation models in NSG mice (211). However, PBMC transfer with 
MV-BiTE treatment further delayed tumor development, as compared to MV-BiTE treatment 
only. This observation supports the hypothesis of a bystander effect by BiTE-mediated T cell 
cytotoxicity. 
Interestingly, 50 % of the TSC23-bearing mice treated with the transfer of PBMCs only 
developed acute graft-versus-host disease (aGvHD) three to four weeks after the PBMC transfer 
(212). T cell receptors (TCRs) of human T cells do not recognize mouse MHC molecules. In 
GvHD-affected mice, human antigen presenting cells (APCs) probably presented mouse 
antigens by MHC class II molecules to CD4+ T cells (213).  However, TSC23-bearing mice 
treated with PBMC transfer and MV-BiTE did not develop GvHD. Presumably, the presence 
of BiTEs directed the T cell activity against the tumor cells and thus prevented the development 
of xenogeneic GvHD. T cell activation and the release of IFNγ are known to upregulate the 
expression of Fas receptor and Fas ligand on both, T cells and tumor cells (214, 215). Thus, T 
cell engagement might result in activation-induced cell death (AICD) of T cells, which in turn 
might prevent the development of GvHD (216).  Interestingly, TSC8- and TSC17-bearing mice, 
which received the transfer of PBMCs only did not show signs of acute GvHD. Median survival 
of TSC8-bearing mice treated with PBMCs only was 20 days after tumor implantation (= 11 
days after PBMC transfer). To the contrary, median survival of TSC23-bearing mice treated 
with PBMCs only was 36 days after tumor implantation (= 30 days after PBMC transfer) 
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Considering that the development of GvHD takes about 20 to 30 days, TSC8-bearing mice 
reached the predefined endpoints of tumor volume or diameter before they could develop signs 
of GvHD. Along the same lines, median survival of TSC17-bearing mice treated with PBMCs 
only was 39.5 days after tumor implantation (= 22.5 days after PBMC transfer). Apparently, 50 
% of the TSC17-bearing mice reached the predefined endpoints of tumor volume or diameter 
before they could develop signs of GvHD. The other half of the mice, which received PBMCs 
only, was as well sacrificed within 30 days after the transfer. Furthermore, as mentioned above, 
the TSC17-bearing mice only received 1/3 of the amount of PBMCs transferred to TSC8- and 
TSC23-bearing mice, respectively. Thus, the probability of developing GvHD may have been 
reduced or development of GvHD may have been delayed, as compared to TSC23-bearing 
mice. 
 
5.6. Potential for Clinical Translation 
Cancer immunovirotherapy has entered clinical practice with the approval of T-VEC by the 
FDA in 2015, an oncolytic herpes simplex virus (HSV) encoding the cytokine GM-CSF 
(chapter 1.3.3 and references therein). More OVs encoding immunomodulators are currently in 
advanced stages of clinical development and demonstrate promising results (chapter 1.4.1 and 
references therein). Oncolytic measles viruses offer a promising vector platform with a modular 
design. One or more transgenes can be inserted at various positions into the MV genome 
without compromising viral replication capacities or oncolytic activity (148). Furthermore, MV 
vaccines possess a proven safety record and recombinant oncolytic MVs, derived from the 
Edmonston vaccine strain demonstrated evidence of safety and efficacy in phase I clinical trials 
(150-153). No dose-limiting toxicities have been reported in ongoing phase I and II clinical 
trials to date (NCT02364713, NCT02068794, NCT00390299, NCT00450814, NCT02192775, 
NCT01503177, NCT01846091, NCT02700230). Furthermore, the MV H protein can be 
modified to ablate viral tropism for the natural cellular receptors (217). MVs can be retargeted 
to specific cellular receptors by introducing an scFv at the C-terminal end of the H protein 
(218). Thus, MV tissue specificity can be altered to enhance tumor selectivity and thereby 
further increase its safety profile. Additionally, tumor selectivity can be increased by 
introducing microRNA-target sequences into the MV genome (219). Thus, viral spread is 
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limited to tissues with an aberrant microRNA expression profile, which is often found in tumor 
cells (220-224). Considering these aspects, the MV-BiTE constructs offer a flexible vector 
platform in terms of tissue targeting and safety. Thus, a personalized drug can be provided, 
given that relevant biomarkers can be predicted or evaluated in advance to therapy. Such 
biomarkers would comprise tumor susceptibility to MV infection, antigen expression and 
miRNA expression. 
The studied MV-BiTE constructs were designed in a way that the encoded scFv domains in the 
BiTE cassette can be exchanged by any targeting domain of choice. Thus, MV-BiTE vectors 
can be adapted to target any tumor surface antigen. Furthermore, several MV-BiTE vectors 
could be administered concurrently or sequentially, which encode for BiTEs targeting different 
tumor antigens to prevent outgrowth of antigen escape variants. Furthermore, the CD3-targeting 
domain could be exchanged by domains targeting macrophages and NK cells (225, 226), 
neutrophils and monocytes (227), enzymes and prodrugs (228), other viral vectors (229) or 
radionuclides (230). Thus, the MV-BiTE constructs offer a flexible vector platform for the 
tumor-targeted delivery of various classes of bispecific antibodies. As discussed above, BiTEs 
did not add meaningful therapeutic effects to MV treatment in the MC38-CEA model. 
However, in the B16-CD20-CD46 model, survival of mice was significantly prolonged after 
MV-BiTE treatment, as compared to mice treated with unmodified MV. As discussed above, 
these findings might result from the distinct immunological landscapes of the different tumor 
models. Thus, evaluating the given tumor immune contexture could serve as another biomarker 
to predict MV-BiTE therapeutic efficacy. Moreover, the flexible MV-BiTE vector platform can 
be adapted to encode the potentially most effective bispecific antibodies, as described above. 
Thus, MV-BiTE therapy offers the possibility for tumor-targeted delivery of personalized 
immunotherapy. 
A major advantage of tumor-targeted expression of therapeutic transgenes is to increase drug 
concentrations at the tumor site while lowering systemic exposure, as compared to systemic 
drug administration. There are two major limitations in systemic BiTE therapy: 1.) Poor 
efficacy against solid tumors; 2.) Dose-limiting toxicities (chapter 1.3.4 and references therein). 
As discussed in chapter 1.4.2, targeted expression of BiTEs by the MV-BiTE approach has the 
potential to overcome both limitations. Along the same lines, we did not observe signs of MV-
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BiTE-related toxicities in the in vivo studies. Moreover, repeated intratumoral injections of 
MV-BiTE did not lead to detectable systemic exposure to BiTEs (Figure 4.14 and 4.18). 
Conclusively, MV-BiTE therapy offers a safe and flexible approach for personalized cancer 
immunotherapy. To provide informed treatment decisions, biomarkers need to be predicted or 
identified in advance to therapy. For biomarker analysis of tumor samples, different 
technologies could provide information on a 1.) Cellular level (susceptibility to MV infection, 
immune contexture): Inoculation of tumor material with MV, flow cytometry, enzyme-linked 
immunospot (ELISpot) assay with TILs, immunohistochemistry, immunosequencing; 2.) 
Genomic/proteomic level (IFN type I status, tumor antigens, prediction of neoantigens, 
clonallity of neoantigens, mutational load): application of bioinformatics to tumor samples 
subjected to multiplexed gene expression profiling, next generation sequencing or protein 
microarrays (231-234). The required technologies for biomarker analysis are developed and 
available, thus, biomarker analysis should be included in future MV-based clinical trials to 
determine the predictive power of the respective biomarkers. Notably, the NCT Precision 
Oncology Program (NCT-POP) and the DKFZ Heidelberg Center for Personalized Oncology 
(DKFZ-HIPO) offer a program with patient-derived tumor samples for the identification of 
predictive biomarkers for susceptibility to MV infection (unpublished data). Moreover, 
biomarker analysis will be included in a MV-based Phase I/IIa trial (CanVirex) by Ungerechts 
et al.. The CanVirex study is currently in preparation at the NCT and will investigate safety and 
mode of action of a combination of oncolytic MV with the anti-PD1 antibody pembrolizumab, 
based on results obtained by Engeland et al. (92). 
 
5.7. Summary and Outlook 
This study reports on oncolytic measles viruses, which were genetically engineered to encode 
bispecific T cell engagers (MV-BiTE). MVs were generated to encode BiTEs targeting human 
or mouse CD3 and the tumor-associated antigens human CEA and human CD20, respectively. 
The replication capacity and oncolytic activity of MV-BiTE was not impaired by encoding the 
additional transgene, as compared to the unmodified MV. MV-BiTE-infected cells expressed 
and secreted BiTEs and specific binding of BiTEs purified from the supernatant of MV-BiTE-
infected cells was demonstrated by ELISA, magnetic pull-down of BiTE-labeled cells and flow 
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cytometric analyses. The potential of BiTEs to mediate T cell cytotoxicity was verified by LDH 
release assays with murine T cells and human PBMCs. Thus, this study demonstrates the 
feasibility to express functional BiTE antibodies by a negative-strand RNA virus. Therapeutic 
efficacy of MV-BiTE was investigated in immunocompetent and xenograft mouse models. 
MV-BiTE demonstrated therapeutic efficacy against the syngeneic melanoma model B16-
CD20-CD46, however not against the syngeneic colon adenocarcinoma model MC38-CEA. 
Survival analysis of B16-CD20-CD46-bearing mice treated with UV-inactivated MV-BiTE and 
purified BiTE indicated that oncolytic activity might not be relevant in the murine tumor 
models, which is supported by work previously published by Veinalde et al. (76, 208). Thus, 
the BiTE-mediated mode of T cell activation seems not to be beneficial in the MC38-CEA 
model. Analysis of tumor-infiltrating lymphocytes indicated that the distinct immunological 
landscapes of the two different tumor models might determine the therapeutic benefit derived 
by the BiTE mode of action. Ultimately, MV-BiTE demonstrated therapeutic efficacy against 
three different xenografts of patient-derived colorectal cancer spheroids with the transfer of 
human PBMCs. No signs of MV-BiTE-related toxicities were observed and BiTE plasma levels 
of MV-BiTE-treated mice remained below detection limit. Thus, intratumoral MV-BiTE 
therapy might reduce systemic adverse events, as compared to systemic BiTE administration. 
Based on the present study results, the MV-BiTE project is continued in our laboratory. The 
MV-BiTE repertoire will be expanded by BiTEs targeting different tumor surface antigens. An 
MV encoding for human high molecular weight-melanoma-associated antigen (HMWMAA)-
targeting BiTE has been successfully cloned and rescued. Further potential BiTE targets could 
be tumor antigens, such as CD19, CD33, epidermal growth factor receptors (EGFRs), epithelial 
cell adhesion molecule (EpCAM) or prostate-specific membrane antigen (PSMA). Along the 
same lines, the panel of xenograft models of patient-derived tumor cultures could be extended 
by the respective BiTE-targeting tumor entities. It would be worthwhile to further investigate 
the mode of action of MV-BiTE treatment. Mechanistic insights could reveal prognostic 
markers for a given tumor immune contexture. Thus, patients who will likely benefit from the 
MV-BiTE therapy could be selected. Mechanistic investigations should focus on the 
immunomodulatory aspects of MV-BiTE therapy: What is necessary to recruit T cells to the 
tumor site and to what extent can T cells be recruited? Are BiTEs involved in T cell recruitment 
to the tumor site or does T cell recruitment rather depend on the immunogenicity of the 
(oncolytic) MV vector? What are the necessary preconditions to initiate/modulate an 
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endogenous antitumor immune response and immunological memory? How does a given 
immunosuppressive TME influence therapeutic outcome? Would a combination of MV-BiTE 
therapy with other immunomodulators, such as immune checkpoint inhibitory antibodies result 
in synergistic effects? These questions remain unanswered in the fields of immunotherapy and 
immunovirotherapy to date. To address these questions, Johannes Heidbüchel currently 
explores live imaging technologies to monitor MV and T cell kinetics in vivo. Furthermore, 
Johannes Heidbüchel conducts targeted transcriptome analyses of MV-BiTE-treated mice to 
obtain comprehensive gene expression profiles. 
Conclusively, MV-BiTE therapy demonstrated therapeutic efficacy in preclinical models of 
solid cancers. The MV-BiTE constructs offer a modular platform, which can be adapted to 
target any tumor antigen of choice. Thus, MV-BiTE therapy represents a promising approach 
for personalized cancer immunovirotherapy, with the potential to overcome limitations of either 
the monotherapy with oncolytic MV or BiTE alone. 
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Figure A.1: Susceptibility of B16-CD20-CD46 cells to MV-BiTE infection. The 
susceptibility for MV-BiTE infection of B16-CD20-CD46 cells was compared to Vero cells. 
Cells were inoculated with MV-eGFP-mCD3xCD20 at an MOI of 1. Images were acquired 48 
h post inoculation. Scale bars: 200 µm. 
 
 
 
 
 
Figure A.2: Replication kinetics and cytotoxic capacity of MV-BiTE on B16-CD20-CD46 
cells. B16-CD20-CD46 cells were inoculated with MV-BiTE and unmodified MV at a 
multiplicity of infection (MOI) of 1. (A) Viral progeny were determined by titration assays 12, 
24, 36, 48, 72 and 96 hours post infection. Titration assays were performed in quadruplicates, 
which results in a detection limit of 25 cell infectious units (ciu)/ml. One-step growth curves 
were generated to compare MV replication kinetics in terms of viral progeny in ciu/ml. (B) Cell 
viability was determined in triplicates 24, 48, 72 and 96 hours post infection. Cell viability in 
% was normalized to cell viability of non-infected cells (mock), as described in chapter 3.2.3. 
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Figure A.3: Therapeutic efficacy of MV-BiTE against murine B16-CD20-CD46. 1x106 
B16-CD20-CD46 cells were subcutaneously implanted into the flank of C57BL/6 mice. Mice 
were treated with intratumoral injections of carrier fluid (mock) or 1x106 cell infectious units 
(ciu) of indicated MV on five consecutive days (n = 10 mice/group). Kaplan-Meier survival 
analysis is shown. Log-rank (Mantel-Cox) test was performed for statistical comparison of 
survival curves and p values were corrected for multiple comparisons by the Bonferroni 
method. 
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Figure A.4: Therapeutic efficacy of UV-inactivated MV-BiTE against murine B16-CD20-
CD46. (A) 1x106 B16-CD20-CD46 cells were subcutaneously implanted into the flank of 
C57BL/6 mice. Mice were treated with intratumoral injections of carrier fluid (mock), 1x106 
cell infectious units of MV-mCD3xCD20 or complete (c)UV-inactivated (= replication 
incompetent) MV-mCD3xCD20 or purified mCD3xCD20 BiTE on five consecutive days (n = 
9-10 mice/group). Kaplan-Meier survival analysis is shown. Log-rank (Mantel-Cox) test was 
performed for statistical comparison of survival curves and p values were corrected for multiple 
comparisons by the Bonferroni method. (B) B16-CD20-CD46 cells were inoculated with MV-
mCD3xCD20 and cUV-inactivated MV-mCD3xCD20 at a multiplicity of infection (MOI) of 
1. Viral progeny were determined by titration assays 12, 24, 36, 48, 72 and 96 hours post 
infection. Titration assays were performed in quadruplicates, which results in a detection limit 
of 25 ciu/ml. One-step growth curves were generated to compare MV replication kinetics in 
terms of viral progeny in ciu/ml. (C) Relative quantification of mCD3xCD20 BiTE present in 
the virus suspension. Purified mCD3xCD20 BiTE was titrated on CD20-expressing Granta 
cells. Mean fluorescence intensity (MFI) was measured by flow cytometry. The concentration 
of purified mCD3xCD20 BiTE, which resulted in an equivalent MFI to MV-mCD3xCD20-
stained Granta cells, was used to treat B16-CD20-CD46-bearing mice. 
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Figure A.5: Protective antitumor immunity after treatment with MV-mCD3xCD20. Mice 
in several experiments went into long-term remission after MV-mCD3xCD20 treatment of 
B16-CD20-CD46 tumors. The parental cell line B16 was implanted into the flank of naïve 
C57BL/6 mice and mice in long-term remission. Frequency of tumor rejection in % is shown. 
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Figure A.6: Gating strategy for the analysis of tumor-infiltrating lymphocytes. Flow 
cytometric analysis of tumor-infiltrating lymphocytes (TILs) after MV-BiTE treatment. The 
first gate covers events of size (FSC) and granularity (SSC) expected for murine lymphocytes. 
Single cells were identified by similarities between FSC-A (area)/FSC-W (width) and SSC-
A/SSC-W, respectively. Dead cells were excluded from the analysis by gating on DAPI 
negative events. Lymphocytes were identified by gating on CD3+ cells (PerCP-Cy5.5+ events). 
Next, cytotoxic T lymphocytes (CD8+ cells) and T helper cells (CD4+ cells) within the CD3+ 
population were identified (APC+ and APC-Cy7+ events, respectively). Activated 
(CD8+CD69+) and differentiated (CD4+CD25+) T cells were identified within the respective 
T cell fractions (PE+ and PE-Cy7+ events, respectively). Red arrows indicate the sequential 
gating hierarchy. 
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Figure A.7: Immunostimulatory effects of MV-BiTE treatment in B16-CD20-CD46-
bearing mice. Analysis of tumor-infiltrating lymphocytes (TILs). B16-CD20-CD46 cells were 
subcutaneously implanted into the flank of C57BL/6 mice. Mice were treated with intratumoral 
injections of carrier fluid (mock) or the indicated MV-BiTE on five consecutive days. Tumors 
were explanted one day after the last treatment. Single-cell suspensions were prepared for flow 
cytometric analysis of TIL subpopulations (n = 10 mice/group). Mean values with standard 
deviation are shown. Statistical analysis was performed by one-way ANOVA and p values were 
adjusted for multiple comparisons by Tukey’s test. 
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Figure A.8: Immunostimulatory effects of MV-BiTE treatment in B16-CD20-CD46-
bearing mice. B16-CD20-CD46 cells were subcutaneously implanted into the flank of 
C57BL/6 mice. Mice were treated with intratumoral injections of carrier fluid (mock) or the 
indicated MV-BiTE on five consecutive days. Tumors were explanted one day after the last 
treatment. Cytokine profiles of MV-BiTE-treated mice. Intratumoral cytokines were quantified 
by cytokine bead arrays. Mean values with standard deviation are shown. Statistical analysis 
was performed by two-way ANOVA and p values were adjusted for multiple comparisons by 
Dunnett’s test. 
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Figure A.9: Effects of UV-irradiation on BiTE functionality. (A) Purified hCD3xCEA BiTE 
was irradiated with a UV-dose of 0.75 J/cm2. Functionality of UV-irradiated BiTE was 
compared to non-irradiated BiTE by using lactate dehydrogenase (LDH) release assay. Mean 
of triplicate samples with standard deviation is shown. (B, C) MV-hCD3xCEA or MV-
mCD3xCEA were irradiated with a UV-dose of 0.75 J/cm2. (B) Replication of UV-irradiated 
MV-BiTE. Vero cells were inoculated with UV-irradiated MV-hCD3xCEA and non-irradiated 
MV-hCD3xCEA, respectively. Viral progeny at 48 hours post inoculation were determined by 
titration assay. Viral progeny in cell infectious units (ciu)/ml are indicated. (C) BiTE binding 
of BiTE present in MV-BiTE suspension. Murine splenocytes were incubated with UV-
irradiated MV-mCD3xCEA and non-irradiated MV-mCD3xCEA. BiTE binding to murine T 
cells was detected by anti-His-FITC antibody. 
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